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Es ist auch schön … 
wenn man Rückschläge hinzunehmen gelernt hat, wenn man Niederlagen sich ein-
gestehen kann, wenn man an Ungerechtigkeiten nicht mehr verzweifelt und sich 
selbst immer treu bleibt ohne dabei arrogant zu sein. Wer im Leben immer Glück 
hatte, worauf will der schon stolz sein ? Was hat der für Erfolge ? Wer nie gefallen 
ist, der weiß auch nicht, wie schön es ist, sich hochzurappeln, aufzustehen und den 
Staub abzuklopfen, über sich selbst zu lachen und dem Leben erneut die Zähne zu 
zeigen und alle zu verblüffen, indem er sagt: 
Das Hinfallen gerade eben hat richtig gut getan … 
(Gerhard Feil) 
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Abbreviations  
ACE Angiotensin-converting enzyme 
Ang I Angiotensin I 
AngII Angiotensin II 
ANP Atrial Natriuretic Peptides 
AT1R Angiotensin II type 1 receptor 
AT2R Angiotensin II type 2 receptor 
CK creatine kinase 
CVD cardiovascular diseases 
gp glycoprotein 
H2O2 Hydrogen peroxidase 
HF Heart Failure 
IL Interleukin 
LV left ventricle 
MAPK Mitogen-activated protein kinase 
MI myocard infarction 
MMP metalloproteinase 
RAS Renin - Angiotensin System 
ROS Reactive Oxygen Species 
TGF-β Transforming Growth Factor - β 
TNF-α Tumor Necrosis Factor - α 
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Zusammenfassung 
In Folge eines akuten Myokardinfarkts (MI) kommt es sowohl zu einer ischämie-
induzierten, direkten myokardialen Verletzung, als auch zu einer subsequenten Herz-
verdickung, verursacht durch eine fehlerhafte inflammatorische Reaktion.  Das Renin-
Angiotensin System (RAS) spielt dabei eine besondere Rolle, da es im Zuge einer 
kardiovaskulären Erkrankung zur Beeinträchtigung des akuten kardialen Remodellings 
und der Entzündungsreaktion beiträgt. Der Angiotensin II Typ 2 Rezeptor (AT2R) ist 
auf immunkompetenten Zellen hochexprimiert und in die zellvermittelte Entzündungs-
reaktion des Herzens involviert. Angesichts dessen wird vermutet, dass der AT2R mit 
CD4+ T Zellen, die während der Entzündungsreaktion als Antwort auf die ischämische 
Verletzung rekrutiert werden, interagiert. Deshalb wurden aus peripherem Rattenblut 
nach einem experimentellen MI (MI- induziert) einerseits sowie Patienten mit Herz-
schwäche andererseits CD4+ T Zellen aufgereinigt. Zwei CD4+ T Zellpopulationen 
CD4+AT2R+ und CD4+AT2R- wurden zunächst mittels FACS sortiert. Mittels 
Durchflußzytometrie, Färbung der Cytospin-Präparate und RT-PCR wurde die Reinheit 
der isolierten Zellen und die Expression des AT2R sowie verschiedener Zytokine be-
stimmt. Um den Einfluss des AT2R auf die Zytokinproduktion zu zeigen, wurden die 
beiden CD4+ T Zellpopulationen CD4+AT2R+ und CD4+AT2R- mit AT2R Agonist 
(Angiotensin II) in Kombination mit AT2R Antagonist PD 123319 (PD) behandelt. Ba-
sierend auf diesen Verfahren wurde die CD4+AT2R+ T Zellpopulation im peripheren 
Blut der Ratte und des Menschen definiert. Die aus dem Blut gewonnenen 
CD4+AT2R+ T Zellen zeichneten sich zum einen durch eine hochregulierte Expression 
des Transkriptionsfaktors Forkhead-Box-Protein FOXP3 aus und zum anderen durch 
eine gesteigerte Produktion verschiedener Zytokine (anti- und proinflammatorisch). 
Außerdem führte die Aktivierung des AT2R zu einer erhöhten Produktion des anti-
inflammatorischen Zytokins IL-10 in den CD4+AT2R+ T Zellen, jedoch nicht in der 
CD4+AT2R- T Zellpopulation. Darüberhinaus führte die intramyokardiale Injektion 
von MI-induzierten CD4+ATR+ T Zellen der Milz nach Herzinfarkt an der Ratte zu 
einer Reduktion der Infarktgröße und zu einer Verbesserung der kardialen Funktion. 
Die Ergebnisse der vorliegenden Arbeit zeigen erstmalig einen AT2R-abhängigen Me-
chanismus, der durch die CD4+AT2R+ T Zellpopulation vermittelt wird und die Supp-
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ression der Entzündungsreaktion im Herz steuert. Damit repräsentieren CD4+AT2R+ 
T Zellen eine vielversprechende Zellpopulation für den Einsatz in der regenerativen 
Therapie, sei es durch direkte myokardiale Transplatation, durch die pharmakologische 
Aktivierung des AT2R oder durch eine Kombination beider Möglichkeiten. 
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Summary 
Following acute myocardial infarction (MI) the heart suffers, beside ischemia-induced 
direct myocardial injury, from a subsequent indirect damage through improper in-
flammatory reaction. A wealth of information indicates that the renin-angiotensin sys-
tem (RAS) can interfere with acute cardiac remodelling and inflammation processes 
during cardiovascular injury. Given the recent observations showing that AT2 receptors 
(AT2R) are abundantly expressed in immunocompetent cells and involved in cell-
mediated inflammatory injury, it appears likely that AT2R may exert their actions 
through interfering with CD4+ T cell-involved inflammatory processes in response to 
ischemia-induced cardiac injury. We therefore isolated CD4+ T cells from peripheral 
blood of rats with acute myocardial infarction and donors with heart failure (HF) using 
Ficoll gradient centrifugation and MACS technology. The CD4+AT2R+ and 
CD4+AT2R- T cell populations were further purified by FACS sorting. The purity of 
isolated cells and the expression of AT2R and various cytokines were confirmed using 
FACS analysis, cytospin staining and RT-PCR methods. To study the role of AT2R on 
cytokine production, the CD4+AT2R+ and CD4+AT2R- T cell were treated with AT2R 
agonist (angiotensin II) in combination with AT2R antagonist PD 123319 (PD). Based 
on this, we defined the CD4+AT2R+ T cell subpopulation in the peripheral blood of rats 
and humans. These blood derived CD4+AT2R+ T cells were characterized by 
upregulated expression of the transcription factor forkhead box protein FOXP3 and var-
ious cytokines (anti- and proinflammatory). In addition, AT2R activation enhanced pro-
duction of the anti-inflammatory cytokine IL-10 in the CD4+AT2R+ T cells, but not in 
the CD4+AT2R- T cells. Furthermore, intramyocardial injection of MI-induced splenic 
CD4+ATR+ T cells into recipient rats with MI led to reduced infarct size and improved 
cardiac performance. This study suggests a novel AT2R-mediated cellular mechanism 
via the CD4+AT2R+ T cell subpopulation in suppressing inflammatory injury in the 
heart. The CD4+AT2R+ T cells is a promising population for regenerative therapy, via 
myocardial transplantation, pharmacological ATR activation, or a combination thereof.  
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1 Introduction 
 
1.1 Heart diseases 
On the basis of “the 2012 report on European Cardiovascular Disease statis-
tics”, diseases of the heart and circulatory system, known as cardiovascular diseases or 
CVD belong to the main health problem in Europe. Each year, CVD cause over 4 mil-
lion deaths, reaching nearly half (47%) of all deaths (1). Thereby, the main forms of 
CVD are coronary heart disease (CHD) and stroke.  
Among the group of CHD, there are myocardial infarction, stable angina pector-
is, unstable angina pectoris, heart failure and sudden death. The following section pro-
vides an overview of coronary heart disease: myocardial infarction and one of its con-
sequences: heart failure.  
1.1.1 Myocardial infarction  
Myocardial infarction (MI) is a coronary heart disease leading to myocardial necrosis 
due to significant and succeeding ischemia. Coronary arteries supply heart muscles with 
blood and oxygen. The most common etiological factor, which is responsible for MI, 
atherosclerotic plaque, known also as atheroma, consists of fatty deposits i.e. cholester-
ol, cells like macrophages, blood cells and some amount of connective tissue (Fig.1.1). 
The size/development of MI depends on plaque erosion, which happens due to the ac-
tivity of metalloproteases, resulting in the thinning of the plaque. Nevertheless, by ex-
position of the basement membrane, it additionally initiates platelet accumulation, 
thrombus formation and differing degrees of vasospasm. An acute reduction of blood 
flow occurs, leading to an imbalance in oxygen supply and metabolic demand of myo-
cardial cells. Such a dysproportional state depends on various factors, which contribute 
to the irregularity of oxygen and nutrient supply, therefore causing cell death. The fre-
quency of contractility, stress of the left ventricle (LV), and ionotropic state of myocytes 
are the most influencing, oxygen consumers. Myocyte death, after the ischemia onset, 
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takes usually a finite period to develop, in some animal models less than 20 minutes. 
For complete necrosis of all myocardial cells, at least 2-4 hours or longer are required, 
but this depends on coronary arterial occlusion, the sensitivity of the cardiomyocytes to 
ischemia, and/or oxygen and nutrients require. Usually several hours after myocardial 
necrosis, post-mortem examination of the MI size, macroscopically or microscopically 
is possible. MI can be classified by size: microscopic (focal necrosis), small (<10% of 
the LV myocardium), moderate (10-30% of the LV myocardium), and large (> 30% of 
the LV myocardium), and by location (2)(3)(4). 
 
Fig.1.1:  Injured heart tissue caused by formation of the plaque (modified from http://medical-surgical-
nursing.blogspot.com/ 
Myocardial infarction can be also defined pathologically (acute, healing or healed) and 
clinically (Tab. 1.1 types 1-5). Acute MI happens when polymorphonuclear leucocytes 
are present, and time needed between the onset of the infarction and death is quite fast 
(6h). The phase of cell infiltration can continue for up to 7 days if coronary perfusion 
does not increase and / or myocardial demand does not decrease. A healing infarction is 
characterized by the presence of mononuclear cells and fibroblasts, but 
polymorphonuclear cells are absent. At least 5-6 weeks are required from the healing 
phase until the phase of scar tissue formation, without cellular infiltration, leading to 
healed infarction. Clinically, the various types of myocardial infarction can be classified 
as shown in Tab. 1.1 (4–6) 
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Class Description 
Type 1 Spontaneous myocardial infarction related 
to ischemia due to a primary coronary 
event: plaque erosion and /or rupture, fis-
suring, or dissection 
Type 2 Moycardial infarction secondary to ische-
mia due to either increased oxygen demand 
or decreased supply: coronary artery 
spasm, coronary embolism, anaemia, hy-
pertension, or hypotension 
Type 3 Sudden unexpected cardiac death, with 
symptoms of suggestive myocardial is-
chemia accompanied with a new ST eleva-
tion, or evidence of fresh thrombus in cor-
onary artery by angiography and/or 
autopsy, but death occurring before blood 
samples could be obtained, or at a time 
before the appearance of cardiac bi-
omarkers in the blood 
Type 4a Myocardial infarction with percutaneous 
coronary intervention (PCI) 
Type 4b Myocardial infarction documented by stent 
thrombosis as documented at autopsy 
and/or by angiography  
Type 5 Myocardial infarction associated with cor-
onary artery bypass graft surgery (CABG) 
Tab. 1.1 Clinically classification of different types of myocardial infarction, adapted from  (5) 
1.1.2 Heart failure – as a main consequence of coronary heart disease 
Heart failure (HF) is a complex, clinical syndrome, caused either by structural (myopa-
thy) or functional heart disruption. The main causes for this disorder in 54-75% patients 
are coronary heart diseases (e.g. MI), followed by hypertension in 35-52% of patients, 
and further in 9-20% patients with isolated hypertension and 18-28% cases with idio-
pathic cardiomyopathy. Heart failure begins when an index event produces an initial 
decline in pumping capacity of the heart (7). Thereafter, a variety of compensatory 
mechanisms are activated, including the adrenergic nervous system (8), the renin-
Introduction 
 
 
12 
angiotensin system (RAS) and the cytokine system. These systems are able to restore 
cardiac function to normal homeostatic range, in consequence, the patient remains 
asymptomatic. With time, for a period of years, the sustained activation of these systems 
can lead to secondary end-organ damage within the ventricle, thereby causing a worsen-
ing in cardiovascular functions, here collectively referred to as LV remodeling. These 
patients undergo the transition from asymptomatic to symptomatic heart failure (9). 
From the clinical point of view, there are some characteristic symptoms which are help-
ful in the diagnosis of this complex syndrome: breathless, ankle swelling and fatigue, 
and as the characteristic signs of congestion of systemic veins: peripheral oedema, a 
raised venous pressure, hepatomegaly. Further, cardiac dysfunctions e.g. decrease of the 
ejection fraction, increase of the ventricle dimension, abnormal diastolic flow pattern, or 
LV remodelling, and finally increase of the diastolic filling pressure are other signs be-
ing involved in the examination of HF. Heart failure considered as a syndrome, is not a 
single diagnosis, but it needs multiply-steps of examination with respect to various 
characteristics, or classifications to define the specific kind of heart failure, which is 
closest to the real picture of the heart disease, from which the patient is suffering. There-
fore, beside a simple classification as acute or chronic heart failure, a more specific 
classification exists with respect to cardiac dysfunctions: systolic and diastolic, which 
describe the principal mechanisms mostly used in the clinical practice.  
Systolic dysfunction means that the echocardiographically measured ejection 
fraction value of the left ventricle (LVEF) is less than 40%.  With so-called systolic 
“forward” failure, blood pressure and peripheral vasoconstriction decrease. Following 
baroreflex activation, which stimulates alpha- and beta-receptors, the RAS is activated 
with sodium and water retention, and oedema formation. Due to the volume backlog, as 
result of the systolic dysfunction, the venous afterload increases and leads to further 
diastolic dysfunction (Fig. 1.2). 
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Fig. 1.2: Demonstration of systolic “forward” failure, modified from (10) 
 
 
Fig. 1.3: Demonstration of diastolic “backward” failure, modified from Weber and Hermann-Lingen, 
2008 (10) 
Diastolic dysfunction is characterized by “backward” failure - even if values of 
LVEF (%) are preserved and coincide with normal range (50% or more), the diagnosis 
of heart failure is accepted. The structure of the myocardium is an essential factor for 
the diastolic features. For instance, when the connective tissue increases after myocardi-
al infarction, this leads to a decrease in the myocardial elasticity and an increase in the 
filling pressure, thereby inducing the pulmonary congestion. Besides that, patients can 
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suffer from impaired breathing and/or pulmonary edema. In the left atrium, atrial natriu-
retic peptides (ANP) are released in larger amounts. Hereinafter, it collectively leads to 
right heart failure with peripheral edema and hepatomegaly (here: the abnormal en-
largement of the liver) (Fig. 1.3)(10–15). Following that, it is classified with respect to 
its severity in accordance to The New York Heart Association classification (15) 
(NYHA classes I-IV):  
I. Class I. No limitation: ordinary physical exercise does not cause an inappropriate 
fatigue, dyspnoea or palpitations. 
II. Class II. Slight limitation of physical activity: comfortable at rest but ordinary ac-
tivity results in fatigue, palpitations or dyspnoea. 
III. Class III. Marked limitation of physical activity: comfortable at rest but less than 
ordinary activity results in symptoms. 
IV. Class IV. Unable to carry out any physical activity without discomfort: symptoms 
of heart failure are present even at rest with increased discomfort with any phys-
ical activity. 
 
1.2 After myocardial infarction – the healing process 
1.2.1 From inflammatory response to the cell death 
Myocardial infarction is associated with an inflammatory response, which is a prerequi-
site for healing and scar formation. The fact that injury causes inflammation (phlogosis) 
was recorded in medical literature by Galen at the beginning of the first millennium. 
There are several mechanisms by which injury can cause inflammation. One of the main 
causes is cell death. By prolonged ischemia, as a major influent of myocardial infarc-
tion, myocardial cells are not sufficiently supplied with oxygen and nutrients, and there-
fore are more predestined to damage and further death. There are two types of cell 
death: necrosis (oncosis) and apoptosis. Cells undergoing necrosis lose membrane in-
tegrity and leak their intracellular components, some of which serve as danger signals 
which stimulate inflammation. Necrotic cell death occurs, in response to some insults 
such as: trauma, infarction (as a result of prolonged ischemia) or toxins. In general, the 
pathological processes are responsible for necrosis. In contrast, apoptotic cell death is in 
majority a consequence of the physiological events (e.g., loss of trophic factors, elimi-
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nation of cells during normal developmental processes, etc.) or in some cases pathologi-
cal events like viral infections (16). The size of apoptotic cells seems to be smaller, but 
the integrity of their plasma membrane is still, at least in the very beginning, main-
tained. While necrotic cell death is influencing the host inflammatory response, apoptot-
ic cells are reacting differently. The maintained integrity of the plasma membrane in 
apoptotic cells protects against any secretion of pro-inflammatory agents (these intracel-
lular components). Contrastingly, these intracellular contents are released from necrotic 
cells. In the apoptotic process of the cell death, it does take time before such compo-
nents are released. Firstly, apoptotic cells are ingested by resident phagocytes, which 
secrete anti-inflammatory cytokines such as interlukin-10 (IL-10) or transforming 
growth factor – beta (TGF-β) which are then responsible for inhibition of any inflamma-
tory response. Apoptotic cells can transition into secondary necrosis, and start to release 
intracellular compartments, only when the phagocytic clearance does not appear on time 
(17).  
The released subcellular membrane compartments are rich of mitochondria, 
which inclusively trigger early acting components: C1, C2, C3, C4 of the complement 
cascade. There is a wealth of information that mRNA and proteins for all of such com-
ponents are upregulated in areas of myocardial infarcts. Moreover, activation of the 
complement cascade can induce infiltration of neutrophils and monocytes to the site of 
injured myocardium. Complement – mediated cascade may lead to leukocyte chemotac-
tic activity as in post-ischemic cardiac lymph during the first hours of reperfusion and 
within the next 3 hours observed (18). Furthermore, the evidence in the whole attribu-
tion to C5a complement in cardiac lymph and blocking of the individual complement 
e.g. C5 by use of antibody-induced inhibition showed, that the activated complement 
cascade plays a role in the initiation of the humoral inflammatory response, particularly 
during the first hours of reperfusion.  
In post-ischemic myocardium, many cellular mechanisms are involved. Reactive 
oxygen species (ROS) are counted among factors which in the ischemic/reperfused heart 
can lead to a deleterious cascade of reactions, so that further myocardial dysfunction 
and/or cytotoxicity are not to overcome. These molecules with unpaired electrons in 
their outer orbit, in normally functioning heart, are transformed as intermediate from 
approximately 5% of the oxygen consumed by tissue, and properly detoxified by enzy-
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matic free radical scavengers (such as superoxidase dismutase, glutathione peroxidise, 
and catalase) or through intracellular antioxidants. At the ischemic/reperfused state or 
during inflammation, their exaggerated production and due to the lacking amount of 
oxygen, leads to the attenuating detoxification process and therefore this initiates harm-
ful radical-mediated reactions. There are plenty of factors, which participate in the gen-
eration of the reactive oxygen species. During inflammatory response, an additional rise 
in the infiltration of circulating blood cells (e.g. leukocytes, platelets) and interaction of 
other cell types (here e.g. coronary endothelial cell and cardiac moycytes), and/or acti-
vation of cytokine cascades, induce excess in the generation of ROS. Necrotic cell 
death, by realising various mitochondrial, sarcoplasmic reticulum and sarcolemma 
compartments, targets ROS and causes myocardial dysfunction. In vitro investigations 
have shown that such free radicals lead to impaired functionality of the isolated mito-
chondria, resulting in adenosine (ATP) depletion and induction of Ca
2+
-overload 
(19)(20)(21). 
The elevated level of free radicals, and secretion of cytokines such as tumour 
necrosis factor-alpha (TNF-α) and interleukine 1-beta (IL-1β) in myocardial infarction 
activates NF-кB family of transcription factors. Thereafter, these induce various genes 
responsible for inflammatory response, cell adhesion and growth control. It has been 
reported that the activation of NF- кB can mediate an injurious, but also cytoprotective 
response (22)(23). An inflammatory response can be demonstrated by an upregulation 
of various cytokines, secreted either by resident or circulating blood-derived cells. Be-
sides of TNF-α and IL-1 cytokines which are involved in the inflammatory response,  
IL-6 level increase in the post-ischemic heart. 
TNF-α. Release of this cytokine occurs rapidly in the central ischemic zone dur-
ing infarction (at maximum in the border zone), acting on several cell types such as leu-
kocytes, endothelial cells, fibroblasts and cardiac myocytes. It was reported that within 
30 minutes after direct hemodynamic stretch, de novo intramyocardial production of 
TNF-α occurs. Furthermore, hydrogen peroxidase (H2O2) can activate TNF-α produc-
tion via p38 mitogen-activated protein kinase (MAPK) followed by myocardial dys-
function and apoptosis. A possible role in the postinfarction inflammatory response may 
be clarified by a model of TNF- α deficient mice with induced myocardial infarction, 
where its absence was manifested by decreased expression of chemokines and adhesion 
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molecules. An elevated level of this cytokine may return to baseline, if the size of in-
farction reveals as small, but if inflammatory response and/or infarction tend to be large, 
an exuberant TNF- α production, predominantly in correlation with enhanced angioten-
sin II type 1 receptor (AT1R) expression, activates local matrix metalloproteinases (e.g. 
MMP) in the infarct area and increases natriuretic peptides (ANP, BNP) and collagen 
expression in the non-infarcted tissue(24)(25).  
IL-6. All IL-6-related cytokines function through multisubunit receptors that 
share the transmembrane glycoprotein (gp)130. In the post-ischemic myocardium, the 
synthesis of these inflammatory cytokines is activated in mononuclear cells and cardiac 
myocytes. While one member of the IL-6 family, cardiotrophin-1 (CT-1) exhibits its 
functions in cardiac myocytes by an induction of hypertrophy, as by Pennica and 
coworkers (1995) discovered, IL-6 does not exert such a function, due to a rare presence 
of the IL-6 receptors on cardiomyocytes (26). Interestingly, this function was activated, 
when a soluble form of IL-6 (sIL-6) was present, at least in vitro (27). Nian at al. (2004) 
(28) demonstrated that beside the ischemic stress, the mechanical stretch of the myocar-
dium can markedly stimulate cytokine production. Through a rapid induction of phos-
phorylation, here the activation of gp130 and STAT3 in cardiomyocyte culture, evident-
ly showed, that IL-6-related cytokines act through the STAT3 pathway. Furthermore, the 
neutralizing TNF-α function, partly inhibited IL-6 upregulation suggesting an important 
role for TNF- α as the upstream cytokine inducer. Cross-talk between the level of TNF-
α and IL-6 expression was observed in the ischemic heart after degranulation of mast 
cells that induced the secretion of TNF-α, and immediately influenced infiltrated mono-
nuclear cells to release IL-6 cytokine. Moreover, in serum of patients suffering from 
myocardial infarction elevated levels of IL-6 were observed, as well as an increased 
creatine kinase (CK) activity on the first and third days of the disease, demonstrating a 
characteristic correlation of both parameters. Additionally, in serum of patients with 
transmural myocardial infarction (associated with atherosclerosis) the highest level of 
IL-6 was detected (29). 
In the post-ischemic setting, an infiltration of neutrophils occurs and due to their 
large size and a stiff form, easily reach capillary endothelium where adhere. This step is 
locally important to amplify the initiated inflammatory response triggered by cytokines 
(28). The activated neutrophils can induce vasoconstriction and platelet aggregation. 
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The cell-mediated inflammatory response (innate immune response) depends on interac-
tion of leukocytes with endothelial cells, which are usually controlled by adhesion mol-
ecules (such as selectins, β2-integrins and the immunoglobulin superfamily). One mem-
ber of the selectin family, is L-selectin (CD62L), which with its broad expression on 
circulating leukocytes: neutrophils, monocytes, eosynophils, T cells and B cells (30)(28) 
is able to promote leukocyte attachment and rolling along post-capillary venules. Oth-
ers, namely P-selectins (CD62P) were found on endothelial cells, and in normal state 
are stored in Weibel-Palade bodies, but after induction by oxygen radicals, thrombin, 
complement components, histamine or hydrogen peroxide, translocate to the surface 
membrane (31). It was stated that 90 minutes after ischemia onset, P-selectins were ex-
pressed on endothelial cells. The presence of the third member, E-selectin (CD62E) was 
observed later, during 4-6 hours of reperfusion (32).  
Platelet activating factor (PAF) is one of a large group of factors responsible for 
β2-integrin activation. This integrin family, named also as CD11/CD18 complex, consti-
tutively expressed on neutrophils, is initially stored in granules, but after activation 
moves to the membrane surface. The rolling process of neutrophils on the endothelium 
is a result of interaction of those complexes with their counterligand ICAM-1, expressed 
on endothelial cells. In consequence, the transendothelial migration into the myocardial 
parenchyma causes further physiological effects, e.g. no-reflow, necrosis (33)(31). 
 
 
Fig. 1.4 Representative time-schedule of healing in murine myocardial infarction (modified from 
Nah and Rhee, 2009, (34)). Inflammatory phase is characterized by leukocyte infiltration into injured 
myocardium with induced cytokine and chemokine cascade, following that proliferative phase introduces, 
where dead cardiomyocytes are replaced with granulated tissue, including myofibroblast and fibrotic-like 
cells. Inflammatory reactions are suppressed. Finally, myofibroblasts undergo apoptosis leading to for-
mation of the collagen-based scar. 
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Above described processes, including an activation of cytokine cascades trigger-
ing leukocytes requirement comprehends the inflammatory phase. This phase, as one of 
three known phases, belongs to healing process in myocardial infarction (Fig. 1.4).  
1.2.2 Proliferative phase 
Acute form of the inflammatory phase is temporarily and its resolution is associ-
ated with suppression of cytokine and chemokine cascades, followed by the entire fi-
brous tissue deposition (35). The myocardial tissue initiates a proliferative phase. After 
two days of reperfusion, fibroblast-like cells and myofibroblasts gather at the border of 
the infarct zone and contribute to the formation of granulation tissue. Myofibroblasts, 
due to their activation proliferate and secrete extracellular matrix proteins. For healing, 
wound oxygen and nutrients are provided from newly formed blood vessels. 
Myofibroblasts (differentiated fibroblasts) are phenotypically beneficial for injured my-
ocardium, because they possess a contractile apparatus and can partly substitute dead 
cardiomyocytes, which lost the ability to divide during evolution, and therefore cannot 
replace themselves (3).  
1.2.3 Maturation phase 
When the cellular infiltration decreases, it means that the last and third phase of 
infarct healing, the maturation phase begins. During this phase, myofibroblasts undergo 
apoptosis and neovessels regress, resulting in collagen-based scar formation. The apop-
totic processes in the cardiac scar are milder for myofibroblasts than for those of the 
skin. These modulated fibroblasts are able to stay in their primary form, without enter-
ing apoptosis, even up to 17 years after myocardial infarction, as observed in human 
model (36). 
1.3 The Renin-Angiotensin System (RAS) 
The renin-angiotensin system (RAS) is a hormonal regulatory system involved in 
various tissues, such as brain, kidney, adrenal gland, heart, vessels, with a major func-
tion in controlling of blood pressure and hypertension and further investigations on its 
influence on the pathogenesis of cardiovascular diseases are required. 
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1.3.1 The classical circulating RAS. The angiotensin II 
From a historical point of view, this enzyme was discovered 100 years ago by 
Tigerstedt and Bergman (37). The classical RAS becomes activated with the synthesis 
of renin in the kidney by juxtaglomerular cells localized in the afferent arteriole. Firstly, 
as pro-renin it does not carry any known biologial functions, but later as an active form 
(renin) it is released via exocytosis, controlled by renal baroreceptors, sympathetic 
nervous system, and angiotensin II (AngII). Renin catalytically cleaves angiotensino-
gen, the most important substrate derived from the liver, to form an inactive, 
decapeptide, angiotensin I (Ang I). Angiotensinogen controls levels of systemic circu-
lating angiotensin (Ang) peptides. This enzyme is found also in other tissues, including 
heart, vasculature, kidney and adipose tissues. Furthermore, Ang I is hydrolysed by an-
giotensin-converting enzyme (ACE) into biological active, octapeptide Ang II. The ACE 
is mostly localized on plasma membranes of endothelial and neuroepithelial cells (Fig. 
1.5). While angiotensinogen and renin possess long half-lives, Ang II is removed from 
the circulation within few seconds by peptidases, named angiotensinases 
(38)(39)(40)(41).  
 
Fig. 1.5 The classical renin-angiotensin system (RAS) and its chemistry (Bader, 2010 (41))  
Angiotensin II, the active octapeptide is a major factor of the RAS, and acts 
through its two G protein-coupled receptors: angiotensin II type 1 (AT1R) and angioten-
sin II type 2 (AT2R), which are seven transmembrane glycoproteins with only 32-34% 
homology. Ang II contributes to the regulation of blood pressure through peripheral 
mechanisms, inducing vasoconstriction by acting of AT1 receptors located on vascular 
smooth muscle cells, causing sodium retention. Angiotensin II functions via the sympa-
thetic nervous system, and is involved in diverse effects such as proliferation, differenti-
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ation, regeneration and apoptosis (42)(43). It is already well known that Ang II activity 
is mostly AT1R- related. Since the clinical targeting drugs are responsible for the inhibi-
tory effects on the AT1R-mediated functions, which are regarded unfavorable, the AT2R 
mostly counteracts in such a scenario. 
Angiotensin II type 1 receptor (AT1R). The AT1R was found to be expressed 
predominantly in adults. Whereas in human AT1R is as a single form, rodents possess 
two (with >95% amino acid sequence homology) isoforms of it: AT1Ra and AT1Rb. 
The AT1R is expressed, as experiments with the adult rats have shown, on VSMCs, en-
dothelial cells, in the kidney, liver, adrenal gland, ovary, brain, testis, lung, heart and 
adipose tissues (37). The AT1R is known to mediate most of AngII actions in cardiovas-
cular, renal, neuronal, hepatic manners, and it has been reported that its actions are 
linked to arterial blood pressure, maintenance of electrolyte and water balance, thirst, 
hormone secretion, renal functions and cellular growth(44) (45). 
Angiotensin II
•Ubiquitous expression
•Vasoconstriction
•Aldosterone secretion
•Inhibition of renin (negative 
feedback)
•Tubular sodium reabsorption
•Thirst
•Vasopressin secretion
•Cellular hypertrophy and growth
•Calcium transport
•Promotion of fibrosis
•Amplification of oxidative and
inflamatory processes
•Ubiquitous expression in fetal 
tissue
•Distinctly expressed in adult 
tissues andrepair processes
•Vasodilator
•Antiproliferative
•Antigrowth
•Apoptosis
•Differentiation
•Neuronal regeneration
•Antioxidant?
AT1R AT2R
 
Fig. 1.6 The major hormone of the renin-angiotensin system (RAS) acts through two receptors: AT1R and 
AT2R, which are expressed in different tissues, and mediate various functions. Schema adapted from 
Volpe et al. (44) 
Angiotensin II type 2 receptor (AT2R). The AT2R expression - compared to the 
AT1R – is in adults or in cells in cell culture very low, but is upregulated in fetal tissues 
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(46). The presence of the AT2R after birth is confined to a few organs such as brain, 
adrenal, heart, vascular endothelium, kidney and ovary. Although the AT1R is dominant 
in the adult organism, expression of the AT2R increases under pathological conditions 
as it has been observed during vascular injury (47), myocardial infarction (48)(49), con-
gestive heart failure, renal failure, brain ischemia. Directly after the onset of injury, 
around 10% of the cardiomyocytes express AT2R, and this level does not change during 
the next 24hrs, but significantly increases in expression in 60% of the cardiomyocytes at 
day 7 following MI (49)(50). The AT2R signals via three transduction mechanisms:  
a.   The activation of various protein phosphatses (mitogen-activated protein kinase 
phosphatase 1(MKP-1), SH2 domain containing phosphatase-1 (SHP-1), and 
protein phosphatase 2A (PP2A)) causing protein dephosphorylation   
b.    Activation of the NO/cGMP system (this signal pathway is shared with AT1R, 
after its activation possible that bradykinin is released) 
c.   Stimulation of phospholipase A2 (PLA2) with subsequent release of arachidonic 
acid (regulation of the intracellular pH level by Na
+
/HCO3
-
 symporter system 
(NBC)) 
The AT2R, biologically, is involved in embryonic development, cell differentiation, 
apoptosis, regulation of renal function and blood pressure.  The protective pathway of 
AT2R might be activated to avoid an overstimulation of AT1R. The AT2R-mediated 
functions, as well AT1R-dependent are presented in the Fig. 1.6.  
1.3.2 The local RAS in the heart.  
For many years, it was thought that the circulating RAS is the only one existing 
system. Further observations in the clinical and experimental situation showed that an 
application of the ACE inhibitors and Ang II antagonists protected cardiac tissue, but 
did not block angiotensin II in the circulation (41). After treatment with targeting drugs 
for RAS, measurement of Ang II levels in the plasma were normal, but blood pressure 
remained low. This could be due to an accumulation of this octapeptide in different tis-
sues and organs such as the pancreas, liver, intestine, heart, kidney, vasculature, carotid 
body, and adipose tissue (43). It seems that the concentration of produced Ang II may 
depend on the amount of precursors and enzymes involved in its biosynthesis. There-
Introduction 
 
 
23 
fore, besides the classical RAS, tissue-related RAS is referred to as the local RAS. Be-
cause the earlier sections referred to coronary heart diseases, this section describes the 
local renin-angiotensin system in the heart tissue, and an involvment of the RAS com-
ponents in cardiac manners.  
In 1987 Dzau reported about the production of AngII in the heart. One of the 
compontents of the RAS, angiotensinogen was found in the whole heart, cultured 
myocytes and fibroblasts (51). Mast cells, which penetrate the heart tissue, especially 
after myocardial injury, release renin from their granules (52), but at normal state, the 
amount of this enzyme reveals to be minimal. Moreover ACE is expressed in cardiac 
fibroblasts and coronary endothelial cells. Local AngII influences blood flow and har-
bour ionotropic properties. The crosstalk of Ang II and cardiac sympathetic nerve leads 
to a release of catecholamine. Locally produced angiotensin II plays an important role in 
the induction of cardiac hypertrophy and fibrosis, mediated via the AT1R, whereas the 
AT2R is reported to have an opposite role as already aforementioned. By an activation 
of ROS production, AT1R can induce cardiac hypertrophy and fibrosis, with an immod-
erate proliferation of cardiac fibroblasts, and further overloaded deposition of extracel-
lular matrix in the cardiac interstitium (53). In result, it leads to ventricular stiffness and 
further impairment of diastolic functions. It has been stated that Ang II needs an interac-
tion with cardiomyocytes to induce fibrosis. This evidence may be explained by para-
crine effects, via release of TGF-β. Generally, the local RAS is characterized by an in-
teraction between cardiac myocytes and fibroblasts, which then are involved in the 
progression of cardiac hyperthrophy and fibrosis.  
 
1.4 Immunological aspects following MI. Cross-talk between RAS and 
regulatory T cells 
As already mentioned in the chapter „From inflammatory response to the cell 
death“, MI is associated with an immune response. Physiological inflammatory re-
sponse causes self-repair and protection, while pathological autoimmune response leads 
to ventricular remodeling and heart failure (54).  
A plethora of reports showed that inflammation is a critical factor in the pathogenesis of 
ventricular remodeling induced by MI (55)(56)(30)(57). At the first phase after myocar-
dial infarction, the innate immunity is activated, leading to cytokines and chemokines 
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upregulation, and thereafter attracts their immunological components which infiltrate 
into infarcted area. The presence of so-called immunocompetent cells was reported in in 
vitro experiments by Jankowski M et al. (2010) showing the CD4+ and CD8+ T cells 
infiltration following MI (58). Other evidence of the adaptive immunity was demon-
strated in an in vivo model, where in 1998 Maisel and associates by an adaptive implan-
tation of the activated splenocytes derived from 6-weeks old MI rats into healthy recipi-
ents rats, observed an induced autoimmune myocardial injury (59). Moreover, the 
examined infarct size of recipients reflected the severity of MI-induced donors as well 
as exhibited cellular infiltration in the cardiac lession. 
Two years later, Varda-Bloom and coworkers (2000) reported that cultured lym-
phocytes (defined later as CD8 T lymphocytes using inhibition assay with anti-CD8 
antibodies) obtained from MI animals with healthy nenonatal cardiomyocytes led to 
higher cytotoxic activity against myocytes, in comparison to those derived from sham-
operated group, however, this activity was to a lesser extent or hardly detectable when 
cultured with non-myocyte cells. This observation was related to immune-mediated 
injury, where the cytolytic lymphocytes revealed an autoimmune response to an 
autoantigen (60). The interest in understanding the role of autoimmune reaction to car-
diac proteins in the failing heart was growing over the years. Following MI, a release of 
contractile proteins such as myosin and actin triggers autoimmune reactions. These pre-
viously “hidden” proteins changed in the infarcted milieu, and have been acting as a 
kind of foreign factors and led to produce antibodies (here functioning as anti-heart) and 
antigen - sensitized cytotoxic T lymphocytes. It has been shown that the cellular auto-
immune reaction to cardiac myosin can be detected in patients with acute myocardial 
infarction, underlining an involvement of the immune system and its compartments as 
well (61)(62)(63). 
Furthermore, it is well known that immune cells which are attending in the first 
crosstalk with the present antigens, which have been encountered tissue, can be able to 
keep an information (memorize it) about foreign entered proteins and during their sec-
ondary occurrence are able to react properly, thus preventing the whole organism. These 
cells have been termed T memory cells.  
Noticing the MI as a kind of cellular autoimmune reaction to cardiac myosin, it logical-
ly demands to understand which immunocompetent cells play a role in the control of 
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such deleterious actions. It is well known that T regulatory cells (Treg) play an essential 
role in maintaining immunological insusceptibility to self-antigens and in suppressing 
excessive immune responses deleterious to host (64). Sakaguchi and colleagues have 
shown these cells as a subset of CD4+ T cells expressing IL-2 receptor alpha chain 
(CD25) and a forkhead winged helix  family transcription factor (FoxP3) which are ca-
pable for immunosuppression, in in vitro and in vivo (64)(65)(66).  Recent observations 
regarding the fluctuations in numbers or function of naturally occurring Tregs (mainly 
transcription factor, FoxP3) in autoimmune diseases led to the consensus, that it is con-
sistently necessary to monitor this transcription factor also in other autoimmune-like 
phenomena, such as MI (67) (68). Combining the mentioned issues, researchers were 
intensively seeking for the interplay between adaptive immune response, T cells, T 
regulatory cells and the actions of major peptide of RAS, angiotensin II. Thereby, Guzik 
et al.(2009) (69) have shown that upon long-term infusion of AngII in mice, the number 
of peripheral blood T lymphocytes was increased. Kvakan et al. (70) observed a benefi-
cial role of naturally occurring T regulatory cells after adoptive transfer into AngII-
induced inflamed mice exhibiting cardiac damage. Additionally, the preventive role of 
post-MI activated AT2R-expressing CD8+ T cells secreting IL-10 has been reported by 
our group with the exception that only post-MI activated AT2R-expressing CD8+ T 
cells, which secreted IL-10 reduced the infarction size in MI recipient rats (71). This 
cell population reduced the infarction size in MI recipient rats.  
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2 Aim of the study 
To clarify the inflammatory mechanisms following MI and the activation of RAS, fol-
lowing issues were questioned and should be discussed in the present study: 
-  Identification and characterization of the AT2 receptor within the immune cells 
(CD4) in two species (human, rat) and under different pathophisological condi-
tions (heart failure, myocardial infarction). 
-  Functional evaluation and therapeutic, regulatory benefits of AT2-expressing 
CD4 T cell subset after their intramyocardial injection in rat MI model.  
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3 Materials and Methods 
3.1 Materials  
3.1.1 Devices 
Mini and QuadroMACS

 Separators Miltenyi Biotec, Germany 
MultiStand Miltenyi Biotec 
MJ Mini

 Personal Thermal Cycler Bio-Rad, Germany 
IKA – Sheaker MTS2 Fritz Gössner GmbH, Germany 
FACS LSRII cytometer Becton Dickinson, Germany 
FACS Aria

 sorter Becton Dickinson 
BD FACSCalibur

 cytometer Becton Dickinson 
Leica DMIL, contrast microscope Leica, Germany 
Leica DMLB, fluorescence microscope Leica 
LSM 780 ELYRA PS.1, confocal microscope Carl Zeiss , Germany 
Leica Z6 APO light microscope,with DFC camera Leica 
Millar Instruments MPVS-300 FMI Foehr Medical Instruments 
GmbH, Germany 
Syringe pump MLW, Germany 
Ventilator, SAR-830/P IITC INC., USA 
MxP Stratagene 3000

 QPCR System Stratagene, USA 
Balance CP324S Sartorius AG, Germany 
Vortex-Genie

 2 Scientific Industries, Inc., USA 
Centrifuge 5417R Eppendorf, Germany 
Multifuge 1 S-R Heraeus Thermo Scientific, Germany 
Incubator BBD 6220, Heraeus  Thermo Scientific 
NanoDrop

 1000 Thermo Scientific NanoDrop 
Products, USA 
Shandon cytospin 3 cytocentrifuge Thermo Fisher 
Safe Flow 1.2 Nunc

 Nunc, Germany 
Cryostat Leica 
 
3.1.2 Plastic ware and other accessories 
Nalgene Syringe Filter, 0.2µm  Thermo Scientific  
Prolene suture: 5.0, 6.0 sizes  Ethicon, LLC, USA 
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Steritop

, vacuum bottle top filter, 0.22µm Millipore, USA 
Microscope slides, HistoBond

  Menzel Glaeser GmbH &Co. 
KG, Germany 
Menzel Glaeser Superfrost

 Plus  Thermo Scientific 
Coverslips: 24x50mm, 22x22mm Thermo Scientific 
Neubauer Chamber, Hemacytometer Marienfeld GmbH, Germany 
Menzel Glaeser Superfrost

 Plus  Thermo Scientific 
Prolene 5.0 and 6.0 size  Ethicon, LLC, USA 
Celstar

 Tubes: 50ml, 15ml greiner bio-one, Germany 
Serum and serological pipettes, sterile greiner bio-one  
Rat Heart slicer matrix, model HSRS001-1 Zivic Instruments, USA 
60mm Petri dishes greiner bio-one 
96-well U-bottom Sarstedt AG, Germany 
MS, LS Columns  Miltenyi Biotec 
BD 5ml falcons (with cap), sterile  Becton Dickinson 
MACS pre-separation filters, 30µm Miltenyi Biotec 
Cell strainer: 100µm, 70µm, 40µm Becton Dickinson 
Syringe: 5ml, 10ml, 20ml Becton Dickinson 
Omnican

 50 syringe B. Braun AG, Germany 
Vasofix

 Safety catheter with injection port, Becton Dickinson 
18G x 1¾” 
Filtertips RNase/DNase free: 10µl, 20µl, 1000µl Nerbe Plus, Germany 
K-EDTA Tubes Sarstedt AG 
Millar Pressure-Volume Catheter, size 2.0 F, Foehr Medical  
length 30cm, MIL-SPR-838 InstrumentsGmbH 
 
3.1.3 Chemicals 
Novamin - Sulfon, 500mg/ml Ratiopharm GmbH, Germany 
PBS (phosphate buffered saline), without magnesium PAA Laboratories  
and calcium  GmbH, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma, Germany 
Bovine Serum Albumin (BSA) Sigma 
Ammonium chloride (NH4Cl) Sigma 
Potassium bicarbonate (KHCO3) Sigma 
Sodium phosphate dibasic (Na2HPO4) Sigma 
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Sodium phosphate monobasic (NaH2PO4) Sigma  
Potassium dihydrogen phosphate (KH2PO4) Merck, Germany 
Sodium chloride (NaCl) Roth, Germany 
Potassium chloride (KCl) Merck  
Sucrose Sigma  
Magnesium chloride-Hexahydrate (MgCl2 x 6 H2O) Serva, Germany 
Glycine, ACS Reagent Sigma  
Pennicilin/Streptomycin Gibco, USA 
Paraformaldehyde (PFA), powder Sigma  
Formaldehyde, 37% Roth 
Fetal Bovine Serum (FBS, inactivated) Gibco 
4’,6-diamidino-2-phenylindole, dihydrochloride Molecular Probes , USA 
(DAPI) 
Fluorosave 

 Reagent Calbiochem, USA 
VECTASHIELD

 Mounting medium with DAPI Vector Laboratories, Inc., USA 
FixoGum Rubber cement  Maruba GmbH & Co. KG, 
Germany 
IGEPAL

  Sigma 
Ethanol Sigma 
Isopropanol J.K. Baker, Germany 
Hydrochloric acid (HCl) Sigma 
Acetic acid, glacial J.K. Baker 
Chloroform   Sigma 
DEPC-treated water  Ambion, USA  
Nuclease-free water  Ambion 
RNaseZAP
 
Ambion 
Trizol

 Reagent Invitrogen, Germany 
BD Perm/Wash

 buffer (10X)  Becton Dickinson, Germany 
Donkey serum Sigma 
Random primers Promega Corporation 
RNase Inhibitor Promega Corporation 
Oligo dNTPs Promega Corporation 
SYBR Green

 Power universal Master Mix (2X) Applied Biosystem, Germany 
Angiotensin II Sigma 
PD123319 Tocris Bioscience, Germany 
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Fast Green FCF Sigma 
Sirius Red Division Chroma, Germany 
Dobutamine Sigma 
Ketamine/Xylazine Sigma 
Phorbol-12-myristate-13-acetate (PMA) Calbiochem 
Ionomycin Calbiochem 
Monensin eBioscience, Germany 
Trypsin  PAN Biotech, Germany 
Tissue Tek O.C.T.   Sakura Finetek Europe B.V., the 
Netherlands 
Pertex
 
mounting medium for histology Medite GmbH, Germany 
Protein Block serum-free Dako, Denmark 
Antibody diluent Dako 
Vybrant

 Cell-labeling solutions Molecular Probes 
BD FACS Flow

 Becton Dickinson 
 
3.1.4 Enzymes 
Collagenase Type 2, CLS 2 Worthington, USA 
Pepsin from porcine gastric mucosa Sigma 
SuperScript

 II Reverse Transcriptase (10.000U/µl)  Invitrogen 
 
3.1.5 Kits 
PicoPure

 RNA Isolation kit  Arcturus, Germany 
DNase Digestion kit Promega Corporation, USA 
M-MLV Transcription kit  Promega Corporation 
Rat IDetect

 Chromosome Y FISH Paint Probe, RED Cambio Ltd, United Kingdom 
RNase Inhibitor Promega Corporation 
 
3.1.6 Antibodies 
Primary Ab Clone Company Staining 
CD4-PE SK3 eBioscience E 
AT2R rabbit polyclonal H-143 Santa Cruz Biotechnology E 
AT2R goat polyclonal C-18 Santa Cruz Biotechnology E 
IL-2 APC MQ1-17H12 eBioscience I 
IL-10 eFluor 450 JES3-9D7 eBioscience I 
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IL-4 Pe-Cy7 8D4-8 eBioscience I 
IFN-gamma APC B27 Becton Dickinson I 
IL-6 PE MQ2-13A5 Becton Dickinson I 
CD4 PerCP SK3 Becton Dickinson E 
IFN-gamma APC 25723.11 Becton Dickinson I 
CD44 eFluor450 IM7 eBioscience E 
CD62L PeCy7 DREG-56 eBioscience E 
Fig. 3.1.Primary antibodies used for cytometry analysis of human samples (EU SICA Study); E: extracel-
lular, I: intracellular  
 
Secondary Ab Company 
Alexa Fluor 488

 donkey anti-rabbit IgG (H+L) Molecular Probes 
donkey anti-goat IgG (H+L) – APC   R&D Systems  
donkey anti-rabbit IgG – PE  Santa Cruz Biotechnology 
Fig. 3.2. Secondary antibodies used for cytometry analysis of human samples (EU Study) 
 
3.1.7 PCR primers 
Primers were purchased from Tib-MolBiol (Berlin, Germany) 
Gene Real –Time PCR primer sequence (5’  3’) 
AT2R Forward: AATATGAAGGGCAACTCCAC 
Reverse: TTAAGACACAAAGGTCTCCAT 
 
18s Forward: CCTGAGAAACGGCTACCACAT 
Reverse: TTCCAATTACAGGGCCTCGA 
Fig. 3.3. Human Sybr Green

 Real-Time PCR primers 
Gene Real –Time PCR primer sequences (5’  3’) 
AT2R  Forward: AATCCCTGGCAAGCATCTTATGT  
Reverse: CGGAAATAAAATGTTGGCAATG 
 
IL-6 Forward: ATATGTTCTCAGGGAGATCTTGGAA 
 Reverse: AGTGCATCATCGCTGTTCATACA 
 
IL-10 
 
Forward: AAGGCAGTGGAGCAGGTGAA 
Reverse: CGTAGGCTTCTATGCAGTTGATGA 
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β-actin Forward: ATCGCTGACAGGATGCAGAAG 
Reverse: CGCTCAGGAGGAGCAATGAT 
  
Fig. 3.4. Rat Sybr Green

 Real-Time PCR primers 
3.1.8 Media and buffers 
Aliquots of phosphate buffered saline were autoclaved before use. All prepared media 
and buffers were sterile filtered with available 0.2µm filters. 
PBS/2mM EDTA buffer 0.744g EDTA 
ad 1L PBS (1X) 
PBS/2mM EDTA/0.5% BSA (MACS Buff-
er) 
0.744g EDTA 
5g BSA 
ad 1L PBS (1X) 
PBS/ 0.5% BSA buffer 2.5g BSA 
Ad 500ml PBS (1X) 
Erythrocyte Lysis Buffer 1.0 g KHCO3 
8.3g NH4Cl 
0.00372g EDTA 
adjust pH to 7.5 ad 1L Aqua dest 
Cell culture medium for lymphocytes: 
(RPMI 1640/10% FBS/1%P/S) 
50ml FBS 
5ml Pen/Strep 
in 500ml RPMI 1640  
Cell culture medium for myocytes isola-
tion: (DMEM/1%P/S) 
5ml Pen/Strep 
in 500ml DMEM medium  
Fig. 3.5. Overview of prepared media and buffers 
 
Dulbecco’s modified medium Eagle medium (DMEM) PAN Biotech GmbH, Ger-
many 
(with 4.5g/l glucose, L-glutamine) sterile 
 
Roswell Park Memorial Institute 1640 (RPMI 1640)    PAA Laboratories GmbH 
(with L-glutamine), sterile      
Lymphocyte Separation Medium (LSM, 1077 g/l)  PAA Laboratories GmbH  
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10% Formalin, neutral buffered (~31ml) 3.125ml Formaldehyde 37% 
28.125ml DEPC –treated water 
0.125g NaH2PO4 
0.203g Na2HPO4 
1M glycine 7.5g glycine 
80ml Aqua dest 
Adjust to pH 8.5 and fill up to 100ml, ster-
ile filter 0.2µm 
1M MgCl2 20.3g MgCl2 x 6H2O  
ad Aqua dest to 100ml 
autoclave to sterilize 
10X Phosphate buffered saline (PBS 10X) 2.0g NaCl 
0.05g KCl 
0.36g Na2HPO4 
0.06g KH2PO4 
Fill up to 25ml with DEPC-treated water 
1X PBS  5ml 10X PBS 
Fill up to 50ml with DEPC-treated water 
2.5% Formaldehyde 2.5ml 10% Formalin, neutral buffered  
7.4ml 1X PBS (in DEPC-treated water) 
0.5ml 1M MgCl2 
2X SSC buffer, pH 7.0 0.5ml 20X SSC 
ad 4.5ml DEPC-treated water, adjust pH to 
7.0 
“2X” Solution (2X SSC/0.1% IGEPAL) 5ml 20X SSC buffer 
45ml DEPC-treated water 
0.050ml IGEPAL

 
“0.4X” Solution (0.4X SSC/0.3%IGEPAL) 0.4 20X SSC buffer 
19.6 DEPC-treated water 
0.060ml IGEPAL

 
0.005% Pepsin Working solution 0.5ml 1N HCl 
49.5ml DEPC-treated water 
Warm up to 37°C and ad 25µl 10% Pepsin 
Fig. 3.6. Overview of prepared buffers for fluorescence in situ hybridization (FISH) 
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3.1.9 Software 
IOX 1.8.3.20 software   Emka technologies, France 
BD FACS Diva software   Becton Dickinson 
BD CellQuest Pro

   Becton Dickinson 
Adobe Photoshop CS   Adobe Systems Inc., USA 
Software ZEN 2010 D   Carl Zeiss AG 
Image J, Java image processing programme Research Services Branch 
(RSB), USA 
ABI Prism 7000 software Applied Biosystems 
AxioVision LE Rel. 4.5 software  Carl Zeiss AG 
WinMDI (Windows Multiple Document Interface  The Scripps Research  
for Flow Cytometry) Institute, USA 
  
 
3.2 Methods 
3.2.1 Induction of myocardial infarction (MI) 
For the animal experiments, we used male Wistar rats (177-200g, Charles River Labora-
tories, Germany). Animals were kept under standardized conditions (temperature, hu-
midity) and housed in the 12-hour light/12-hour dark cycle with food and water ad 
libitium. All experiments were performed according to the state regulations and ap-
proved by the responsible authorities of Landesamt für Landwirtschaft, 
Lebensmittelssicherheit und Fischerei Mecklenburg-Vorpommern. Myocardial infarction 
in the rats was surgically induced by ligation of the left anterior descending coronary 
artery (LAD) as described (71–73). After anesthesia with ketamine/xylazine 
(80mg/10mg/kg body weight, intraperitoneally), rats were intubated and connected to a 
small-animal ventilator. After opening the chest, the heart was carefully cleaned with the 
tap with saline and the ligature using a suture (size 6.0) was performed. For the sham-
operated (Sham-OP) group of animals, all steps were included besides the ligature. Only 
for animals which underwent the LAD ligation, 15 drops of Novamin-Sulfon were giv-
en to 300ml of water per day. Seven days after MI induction or Sham-OP, rats were sac-
rificed and blood from the periphery of the hearts was collected in a syringe coated with 
PBS/2mM EDTA, and hearts and spleens were excised. For transplantation experi-
ments, the recipient female rats were subjected to the same standardized method for MI 
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induction, as described above. Randomly taken MI recipient rats were subdivided into 
three groups which obtained as follows either saline (as control group) or 
CD4+AT2R+/- T cells (as cell therapy group). 
3.2.2 Human peripheral blood involved in in vitro experiments 
Peripheral venous blood was obtained from patients with a clinical diagnosis of chronic 
HF according to current guidelines of the European Society of Cardiology and American 
Heart Association at the Department of Cardiology, Campus Virchow – Klinikum. 
Blood from healthy donors was obtained from the Institute for Transfusion Medicine, 
Charité-Universitätsmedizin Berlin. Written informed consent according to the Declara-
tion of Helsinki was received prior to inclusion in the study. Around 25 ml of blood was 
obtained from an antecubital vein and transferred to K-EDTA monovettes and processed 
within 8 hours.  
3.2.3 Isolation of human/rat blood and rat spleen CD4 + T cells 
Rat and human blood. Peripheral blood, which was withdrawn from the periphery 
either of MI or Sham-OP rats was transferred to EDTA-K tubes and carefully mixed to 
avoid agglutination. Rat blood was diluted with PBS/2mM EDTA buffer in ratio: 1:3. 
Human blood samples were diluted with PBS/2mM EDTA buffer at least two times. 
Either rat or human blood samples were layered on Ficoll

 Lymphocytes Separation 
Medium (LSM) and centrifuged at 400xg for 35 minutes at room temperature (RT) at 
low acceleration and without using a brake. Mononuclear cells were collected from the 
white interphase, washed twice with cold PBS and red cells were lysed by adding cold 
Erythrocyte Lysis Buffer. Cell aggregates were removed by a filtration step with 30µM 
pre-separation filters, an aliquot of cell suspension was taken for counting of total cell 
number using Neubauer Chamber and during that, cells were washed at 300xg at 4°C 
for additional 10 minutes. Further immunofluorescence stainings of the isolated MI-
derived rat and healthy human blood cells were performed as shown in table 3.2.1 and 
processed further for FACS sorting as in the next section described.  
Spleen of male MI rats. After incision of peritoneal layer, spleen tissue of male MI rats 
was removed and transferred to a cold HBSS without Ca
2+
 and Mg
2+
. Tissue was placed 
in a 60mm Petri dish with 3ml cold DMEM/1% Pen/Strep, cut into 1mm pieces and 
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immediately filtered through 100µm filter using syringe plug. Following a centrifuga-
tion step at 300xg at 4°C for 10 minutes, erythrocytes were lysed and remaining cells 
were filtered through 30µm pre-separation filters to remove cell aggregates. Spleen 
mononuclear cells were washed once more with a cold MACS buffer, counted and 
stained as in the table 3.2.1 (rat spleen) presented.  
Step Rat blood (MI) Rat spleen (MI) Human blood 
(HD, HF) 
Primary anti-
body (dilution) 
30min at 4°C, in 
the darkness 
Mouse anti-rat 
CD4-PE (1:10), 
polyclonal rabbit 
anti-AT2R (1:50), 
donkey serum 
(1:50) 
Fill with a cold 
MACS buffer up 
to 200µl volume 
Mouse anti-rat 
CD4-PE (1:10), 
polyclonal rabbit 
anti-AT2R (1:50), 
donkey serum 
(1:50) 
Fill with a cold 
MACS buffer up 
to 400µl volume 
Mouse anti-human 
CD4-PE (1:10), 
polyclonal rabbit 
anti-AT2R (1:50), 
donkey serum 
(1:50) 
Fill with a cold 
MACS buffer up 
to 400µl volume 
Washing step I Add 5ml of a cold MACS buffer and washed at 300xg at 4°C 
for 10 minutes 
Secondary anti-
body (dilution)  
30min at 4°C, in 
the darkness 
anti-PE 
MicroBeads 
(1:10), donkey 
anti-rabbit Alexa 
Fluor 488 (1:50) in 
volume up to 
200µl in MACS 
buffer 
anti-PE 
MicroBeads 
(1:10), donkey 
anti-rabbit Alexa 
Fluor 488 (1:50) in 
volume up to 
400µl in MACS 
buffer 
anti-PE 
MicroBeads 
(1:10), donkey 
anti-rabbit Alexa 
Fluor 488 (1:50) in 
volume up to 
400µl in MACS 
buffer 
Washing step II Add 5ml of a cold MACS buffer and washed at 300xg at 4°C 
for 10 minutes 
Fig. 3.7  Tabular protocol of an indirect immunofluorescence staining (I) combined with anti-PE 
MicroBeads labeling. HD: healthy donors, HF: heart failure 
Cardiac cells of MI rats. Rats were anesthetized, the abdomen sterilized, beating heart 
was surgically removed and transferred in HBSS (w/o Mg, Ca). The remaining blood 
was flushed out with PBS and the heart was cut into small pieces. Following trypsin 
(O.N. at 4°C, 0.25%, PAN) and Collagenase Type II (0,25mg/ml, 37°C up to 25 min) 
treatment, heart cells were released by passing the tissue aggregates several times using 
a 25ml serological pipette. Subsequently, cells were filtered through 70µm and then 
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40µm cell strainers. Cells were re-pelleted, counted for their viability and used for im-
munofluorescence staining as described in Tab. 3.8. 
Step Rat heart (MI) 
Primary antibody (dilution) 
30min at 4°C, in the darkness 
Mouse anti-rat CD4-FITC (1:10), polyclonal goat 
anti-AT2R (1:50), donkey serum (1:50) 
Fill with a cold MACS buffer up to 200µl volume 
Washing step I Add 5ml of a cold MACS buffer and washed at 
300xg at 4°C for 10 minutes 
Secondary antibody (dilution)  
30min at 4°C, in the darkness 
Anti-mouse IgG MicroBeads (1:5), donkey anti-goat 
APC (1:20) in volume up to 200µl in MACS buffer 
Washing step II Add 5ml of a cold MACS buffer and washed at 
300xg at 4°C for 10 minutes 
Fig. 3.8 Tabular protocol of an indirect immunofluorescence staining (II) combined with MicroBeads 
labeling 
Stained mononuclear blood, spleen or cardiac cells were further applied onto precondi-
tioned MS columns and processed using MACS technology. Columns were placed onto 
a MiniMACS Separator attached to a MultiStand. While magnetically labelled CD4+T 
cells were retained in the column due to the existing magnetic field, unlabeled cells 
were passed through it into a falcon tube as a negative fraction. The CD4+ T cells were 
then eluted by removing the column from the separator and placing onto fresh falcon 
tube (positive fraction). MACS isolated CD4+ T cells of rat or human origin were fur-
ther processed for sorting of CD4+AT2R+ and CD4+AT2R- T cell subpopulations by 
BD FACS Aria

 device. 
3.2.4 Sorting of CD4+AT2R+ and CD4+AT2R- T cells 
Flow sorting is a process that allows the physical separation of a cell or particle of inter-
est from a heterogeneous population. After MACS isolation, cells were resuspended in a 
cold MACS buffer at a concentration less than 2000 cells per second (events/s). Cell 
suspension greater than 2000 events/s declines the efficiency of the sorting process. 
Before sorting, nuclei dye DAPI was added at a final concentration of 300nM to distin-
guish between dead and living cells. The established pressure in the whole FACS sys-
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tem allowed an ejection of cells into air in a stream of sheath fluid (i.e. buffer on the 
basis of phosphate buffered saline). Cells were passed through one or more laser beams 
and information about the fluorescence characteristics of the acquired cell (event) was 
gathered. The different cell fractions were collected, when the cell broke off from the 
solid stream in a droplet. At this moment, cells were charged and then passed through 
two high-voltage deflection plates and were deflected into collection tubes or aspirated 
to waste. Sorted CD4+AT2R+ and CD4+AT2R- T cells were re-pelleted at 400xg at 
room temperature for 15 minutes, to ensure that the sorted cells were settled in the bot-
tom of tube. While rat and human blood T cell fractions were used for cell culture ex-
periments and cardiac T cells for RNA isolation, rat spleen cells were prepared for fur-
ther intra-myocardial transplantation. 
3.2.5 Cell culture of blood sorted cells 
Freshly sorted CD4+AT2R+ and CD4+AT2R- from MI rat or human control blood were 
plated in a U-bottom 96-well plate at a density 10
6
 cells per ml and cultured in RPMI 
1640 medium supplemented with 10% FBS and 1% Pen/Strep and 2mM Glutamine 
under standard cell culture conditions at 37°C, 5% CO2 with 20% humidity. T cells were 
cultured without treatment (control) or treated with AT2 receptor agonist angiotensin II 
(AngII, 0.5nM), pre-treated with AT2R blocker PD123319 (PD, 5nM) for one hour and 
immediately stimulated with angiotensin II (0.5nM). Only human sorted T cells were 
subjected to the treatment. Rat blood cells were cultured without any treatment as a con-
trol. After one day of culture, cells were harvested and processed for intracellular stain-
ing as described in the next section. 
3.2.6 Extracellular staining for flow cytometry 
Blood mononuclear cells of human origin were stained for surface markers (CD4, 
AT2R, CD25), and subjected to an extracellular staining protocol. Firstly, cells were 
blocked with donkey serum to reduce unspecific binding (1:50), indirectly labelled with 
polyclonal rabbit anti-AT2R antibody (1:50), additionally stained with PE-conjugated 
mouse anti-human CD4 and APC-conjugated mouse anti-human CD25 (1:10) antibod-
ies. Secondly, staining for AT2 antigen was complemented by labelling with donkey 
anti-rabbit Alexa Fluor 488 (1:50). Incubation time and washing steps were performed 
as already shown in Tab. 3.7 or 3.8 
Materials and Methods 
 
 
39 
3.2.7 Intracellular staining for flow cytometry analysis 
Following 24-hours culture, cells were stimulated for another 6 hours with phorbol 
myristic acid (PMA, 10ng/ml) and ionomycin (500ng/ml). To keep secreted cytokines 
within cells, monensin (2µM) was added to medium for the remaining 3 hours. The ex-
tracellular staining with anti-CD4 and anti- AT2R antibodies, performed before sorting 
and one day of cultivation did not markedly attenuate fluorescence intensity. Therefore, 
harvested cells were immediately washed once with cold MACS buffer and fixed with 
4% paraformaldehyde for 10 minutes on ice, in darkness. By addition of 0.5 ml of a 
cold PBS and centrifugation at 300xg, 4°C for 10 minutes, fixatives were removed. Fix-
ation was followed by a permeabilisation step with the commercial detergent 
Perm/Wash

 (diluted 10-times with Aqua dest) for another 15 minutes on ice. Above 
mentioned steps were performed in the same way for rat and human cells. Thus fixed 
and permeabilized cells were processed for various direct intracellular stainings. 
Cytokine patterns. The antibodies used for human T cell fractions were: 
allophycocyanin (APC)-conjugated rat anti-human interleukine-10 (IL-10–APC, 1:50), 
APC-conjugated mouse anti human interferon gamma (IFN-γ–APC, 1:10) and 
phycoerythrin-Cy7 (PE-Cy7)-conjugated mouse anti-human tumour necrosis factor-
alpha (TNF-α–PE-Cy7, 1:20), and rat T cells were stained with phycoerythrin (PE)-
conjugated mouse monoclonal anti-rat IL-10 (IL-10–PE, 1:50) for 30 minutes at 4°C, in 
darkness. Perm/Wash

 buffer served here as the antibody diluent. Stained cells were 
washed with cold PBS, resuspended in 0.3 ml PBS and acquired using a BD FACS 
Calibur

 and /or a BD FACS LSRII.  At least 10
3
 cells were recorded and analyzed via 
WinMDI Software and/or FACS DIVA Software 6.2.1. 
Forkhead protein box (FoxP3). The extracellular immunofluorescence stainings, i.e. 
3.2.6 were performed. In rat and human mononuclear blood cells, the transcription fac-
tor forkhead protein box (FoxP3) was detected intracellularly. Rat blood mononuclear 
cells were previously stained with PE-conjugated mouse anti-rat CD4 (1:10) and indi-
rectly labelled with APC-anti-AT2R (1:50) antibodies. Fixation and permeabilisation 
steps followed as stated in the beginning of this section, and cells were then incubated 
with FITC-conjugated anti-mouse/rat FoxP3 (FoxP3-FTIC, 1:10) for 30 minutes in 
Perm/Wash buffer at 4°C, in darkness. By contrast, human blood mononuclear cells, 
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with regard to the extracellular staining section (3.2.6), were stained with APC-
conjugated rat anti-human FoxP3 (FoxP3-APC, 1:10) during the same incubation time 
and way as that of rat origin. Data were acquired on a BD FACSCalibur

 and at least 
5x10
4
 events of the CD4+ gate were recorded. The frequency of the FoxP3-positive 
cells was analyzed among two sub-populations: CD4+AT2R+ and CD4+AT2R-.  
3.2.8 Total RNA isolation and quantitative real-time PCR 
Some samples of sorted or/and stimulated T cells were taken for RNA isolation. 
Total RNA of small cell pellets (3.2.4) was purified by a PicoPure Kit according to 
manufacturer’s recommendations. Collected cells were washed in MACS buffer at 
3000xg for 10 minutes, then after removing the supernatant for additional 5minutes. 
Next, 100µl of supplied Extraction Buffer was added and cells were extracted at 42°C 
for 30 minutes. After a five-minute washing step at 3000xg, supernatant with the ex-
tracted RNA was removed and mixed with an equal volume of 70% ethanol. Complete 
mixture was applied onto preconditioned purification column and following centrifuga-
tion and washing steps, pure RNA was eluted with Elution Buffer into microcentrifuge 
tubes provided in the kit. An alternative method used for RNA extraction was the appli-
cation of Trizol
 
Reagent accordingly to the conventional method (74). Cells were ex-
tracted in Trizol reagent for 15 minutes at room temperature. By applying chloroform 
and 15 minutes centrifugation step at 12000xg, 4°C, aqueous phase contained RNA was 
carefully transferred into a new tube, and precipitated with isopropanol. RNA was cen-
trifuged into a gel-like pellet and washed with 75% ethanol (diluted in nuclease-free 
water). RNA pellet was dried and dissolved in nuclease-free water. The amount of RNA 
was estimated using a NanoDrop device at 260 nm. Reverse transcription to cDNA was 
performed using either Promega reagents (5x M-MLV buffer, M-MLV enzyme, dNTPs, 
Rnasin Inhibitor) or SuperScript II kit, especially when the amount was less then 250ng 
of total RNA. Table 3.9 shows reverse transcription of the purified RNA into cDNA 
when Promega reagents were used.  
Reagents Volume, Time, Temperature  
0.5-1µg of total RNA  8µl 
DNase 1µl 
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DNase Buffer 1µl 
 10µl of the mixture incubated at 37°C for 
30minutes 
DNase Stop solution 1µl -> 10 minutes at 65°C 
Random primers 1µl -> 5 minutes at 70°C 
5xM-MLV Buffer 5µl 
M-MLV reverse transcriptase 0.5µl 
dNTPs (25 mM) 2µl 
RNase inhibitor 0.5µl 
Nuclease-free water 5µl 
 total volume: 25µl 
-> 1 hour at 37°C 
then 4°C and stored at -20°C 
Fig. 3.9 DNase digestion and reverse transcription of isolated RNA  
 
Quantitative real-time PCR was performed using an ABI Prism 7000 and Stratagene 
3000 MXP PCR cycler with the SybrGreen PCR Master Mix (table 3.10) according to 
the following steps demonstrated in the table 3.11. 
Reagents Volume 
SybrGreen

 PCR Master mix (2x) 12.5µl 
Forward primer (20µM) 0.4µl 
Forward primer (20µM) 0.4µl 
Nuclease-free water 6.7µl 
cDNA 5µl 
Fig. 3.10 PCR reaction mixture  
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1. Hot start 95°C 10min 
2. Denaturation 95°C 15s 
3. Primer annealing 60°C 30s 
4. Elongation 60°C 30s, 40 cycles 
5. End  72°C 1min, 1 cycle 
6. Pause  4°C  
Fig. 3.11 PCR-temperature profiles and number of cycles  
3.2.9 Immunofluorescence staining  
Cytospin of cell suspension. Suspensions of the human MACS isolated CD4+ T cells 
were washed once with PBS/BSA 0.5% buffer, counted and resuspended in the 
RPMI1640/2%FBS medium using 1-2x10
5
 total cells and kept cold. Cytospin slides 
were prepared as follows: cytocentrifuged at 1000rpm for 5min, fixed in 1% PFA for 
5min and subsequently blocked with PBS/5% donkey serum/2% BSA for one hour. Fi-
nally, cytospins were stained by indirect double-step immunocytochemistry with prima-
ry antibody polyclonal rabbit anti – AT2R (1:50) for 3 hr at RT and secondary donkey 
anti-rabbit Alexa Fluor 488 (1:100) for 1hr at RT. Nuclei were counterstained with 
DAPI dye for 10 min at RT (300nM). Cytospin slides were visualized by a Zeiss LSM 
780 Microscope with 63x objective magnification and processed using free software 
ImageJ. 
Preparation of cryosections. Following the left ventricular catheterization (or 7 days 
after MI induction), rats were sacrificed (5% KCl), heart tissue was excised and remain-
ing blood removed by flushing with cold PBS. Using a rat heart matrix slicer (model 
with 1.0 mm coronal section slice intervals) the aorta of the base was truncated and then 
heart was embedded in Tissue Tek O.C.T., snap-frozen and stored at -80°C. Samples 
were sectioned into 5 µm from 4 levels (10mm thick) on a Leica Cryostat and placed 
onto HistoBond

 adhesion microscope slides.  
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Staining of heart cryosections from MI rats (7 days). Five-micron cryosections were 
fixed in 4% PFA , blocked with DAKO Protein Block for 10min at RT, and stained indi-
rectly with primary goat polyclonal CD4, rabbit polyclonal AT2 (1:50, both ) at 4°C 
overnight and the following secondary antibodies: donkey anti-goat Alexa Fluor 647, 
donkey anti-rabbit Alexa Fluor 568 (Invitrogen, 1:300, both) for 2 hours at RT, respec-
tively. The nuclei were counterstained with DAPI. Control slides were defined as those 
without primary antibodies.  
3.2.10 Preparation of donor CD4+AT2R+ T cells and intramyocardial 
transplantation 
Donor CD4+AT2R+ and CD4+AT2R- T cells were prepared from spleens of male rats 
seven days after induction of MI. Immediately after LAD ligation, 2.5x10
5
 
CD4+AT2R+ or CD4+AT2R- T cells resuspended in 50 µl saline were injected into the 
border zone of the ischemic myocardium of each recipient female rat. MI rats injected 
with saline served as control group. 
3.2.11 Left ventricular catheterization – pressure/volume-loop 
Four weeks after transplantation, female rats underwent pressure-volume (P/V) loop 
measurements using the Millar Pressure-Volume System (Catheter model SPR-838 (size 
2F, length 12.5cm), Millar Pressure Conductance Unit (model MPCU-200) and 
PowerLab data acquisition hardware (emka Technologies). Following a small incision in 
the external jugular vein, a plastic catheter was inserted and 200UI/kg of heparin was 
administrated. After a short period, up to 0.4 ml blood was collected, immediately ap-
plied into two cylindrical holes with defined volumes (95, 300µl) and calibration of 
volume was performed. Thereafter, calibration of pressure at 0 and 100 mmHg was per-
formed. The right carotid artery was subsequently exposed by a small incision on the 
neck and the lateral retraction of the osmohyoid muscles. After a small incision between 
the two ligatures, the Millar catheter was carefully inserted. To secure the catheter, the 
loose ligature around it was tied. Values of parallel conductance volume (Vp) were ac-
quired via triple injection of saline (5%), averaged and used for correction of conduct-
ance volume. IOX Version 1.8.3.20 software was used to analyze all P/V loop data rec-
orded at steady state (baseline) and under stress conditions (dobutamine, 10µg/kg/min 
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intravenously). Collected data on cardiac performance were divided into three groups: 
hemodynamic parameters and systolic and diastolic indicies. 
3.2.12 Quantitative estimation of collagen density  
From the four-week-old rats which underwent myocardial infarction plus cell implanta-
tion, excised hearts were snap-frozen as described above and divided into two groups: 
induction of MI plus transplantation of the CD4+AT2R+ T cells (MI+CD4+AT2R+) and 
induction of MI + transplantation of CD4+AT2R- T cells (MI+CD4+AT2R-). Sliced 
five-micron sections were fixed in 10% formalin. Following Sirius Red (collagen) and 
Fast Green FCF (myocytes) staining, incubation with increasing alcohol changes, slides 
were mounted with Pertex

 and recorded on Leica DMLB microscope, analyzed with 
Adobe Photoshop.  
3.2.13 Quantitative estimation of infarction size  
The same slides, which were stained for the quantification of collagen density (3.2.12), 
were used for the infarction size estimation. Each section was recorded with the same 
settings using a Leica Z6 APO apochromatic, light microscope (connected to LAD cam-
era and computer). Images were further processed with Axio Vision LE Rel. 4.5 soft-
ware, and the infarcted area (%) was calculated with respect to the whole heart section. 
3.2.14 Methods for the detection of the transplanted T cells 
Labeling of donor cells with Vybrant 
 
DiD dye. There are three different tracking 
dyes available: DiO, DiL, DiD. We chose DiD (V-22887), which usually is detected at 
665nm. Sorted T cells were washed once with PBS and kept overnight at 4°C in DMEM 
medium. Following one more washing step, cells were resuspended at 1x10
6
/ml density 
and usually 5µl of DiD dye was added to one ml of cell suspension. After 10 minutes 
incubation at 37°C (conditions optimal for splenocytes), cells were washed twice at 
400xg for 5 minutes.  Donor cells were resuspended in a defined volume and implanted 
into the heart after myocardial infarction induction in female Wistar rats. Aliquots of 
stained cells were taken and positive DiD- labeled cells were acquired on FACS LSRII 
cytometer to optimize settings and gating strategy. Two days post MI and transplanta-
tion, hearts were excised, cardiac monononuclear cell isolation was performed and data 
were directly acquired on a cytometer to detect presence of donor cells in recipient 
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hearts. The percentage of positive DiD – labeled donor cells was calculated among all 
acquired cardiac cells. 
Detection of the chromosome Y in recipients rats (4 weeks). Slides were subsequent-
ly processed for fluorescence via in situ hybridization (FISH) to detect Y chromosomes 
of donor rat cells. For detection, Rat IDetect
 
Chromosome Y FISH Paint Probe Red 
was used and staining was performed according to manufacturer’s recommendations. 
All buffers and reagents were prepared freshly using DEPC-treated water before stain-
ing, if necessary. Heart slides were transferred from -20°C to room temperature to allow 
them to completely dry. Following denaturation steps by placing slides in 2XSSC buffer 
at 73°C for 2 minutes, slides were then transferred into pre-warmed 0.005% pepsin 
working solution and incubated at 37°C for 10 minutes. Following washing step with 
PBS for 5 minutes at RT, each tissue was fixed by covering it completely in 2.5% for-
maldehyde solution. After 5 minutes, slides were rinsed in PBS (with few drops of 1M 
glycine) for another 5 minutes, and dehydrated with 1 minute in each 70%, 85% and 
100% ethanol solutions at RT.  A mixture of the probe and Hybridization Buffer, which 
were supplied in the kit, were prepared and applied onto tissue, covered with coverslips 
and sealed with rubber cement. Next, probe and chromosomal DNA were co-
denaturated on a hot plate at 69°C for 2 minutes and hybridized at 37°C for 16 hours in 
humidified chamber. Before washing, rubber cement was carefully removed with fine 
forceps and slides were periodically shaken to remove coverslips, and immediately 
transferred to hot “0.4X” solution (set at 73°C) for 2 minutes, and briefly in “2X” solu-
tion for 1 minute. Rinsed slides with DEPC-treated water were air dried and mounted 
with Vectashield

 medium, containing DAPI at 1.5µg/ml concentration. Images were 
recorded using a Zeiss LSM EYLRA P S.1 microscope with 63x objective. Co-
localization of Y
+
 cells was analysed by use of the Ortho function available in ZEN 
2010 software. Recorded images were processed using Adobe Photoshop

 software. 
3.2.15 Statistical analysis 
All results are presented as mean ± SEM. For two group comparisons, two-tailed Stu-
dent t test was used. For multiple groups statistical analysis, one-way-ANOVA method 
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with Bonferroni post-hoc multiple comparisons was used. Differences at a value 
P ≤ 0.05 were considered as a significant. 
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4 Results – Part I / human 
4.1 The baseline characteristic of patients with heart failure.  
Nine patients who donated whole blood within the SICA Study (no. 241558), were en-
closed to the present dissertation and the relevant parameters were included and are pre-
sented as baseline characteristics, see Tab. 4.1. 
Parameters Heart Failure  
n=9 
Age (years) 65.7 ± 4.4 
Sex (male/female) (4/5) 
NYHA functional class (II/III) (4/5) 
Etiology:   
               ischemic and others 
 
9 
LVEF (%) 32.78 ± 5.8 
PM 1 
ICD 4 
CRT 1 
CRT-D 1 
No PM 2 
Medication (%):   
ACE inhibitors 
β-blockers 
AT1R-antagonists 
Diuretics  
Aldosterone-antagonists 
Statins 
Digoxin 
Aspirin 
 
5 (55.6) 
9 (100) 
4 (44.4) 
7 (77.8) 
6 (66.7) 
3 (33.3) 
4 (44.4) 
7 (77.8) 
Tab. 4.1  Baseline characteristics of patients with heart failure.  Taken from Skorska A et al., JCMM 
(2015)  
Values are shown as mean ± SEM. DCM: dilated cardiomyopathy, ICD: Implantable Cardioverter Defib-
rillator, CRT: Cardiac Resinchronization Therapy, PM: Peacemaker, AT1R: angiotensin II type 1 recep-
tor, ACE: angiotensin-converting enzyme 
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The above baseline characteristics show that ischemia was a major cause which led to 
the progression of heart failure. Among the functional NYHA classes, patients were 
classified as II and III. This could explain minimal physical activity caused by an atten-
uated heart function with heart damage and wall thinning during the healing process. 
Moreover, to avoid the second heart attack, patients had undergone drug therapy by ad-
ministration of β-blockers (all patients), AngII-, AT1R- and Aldosterone antagonists, 
ACE and thrombocyte inhibitors (aspirin), and to the less extent (three of nine patients), 
statins, to decrease the cholesterol level. Twenty eight healthy donors were included in 
the present work and served as a control. 
4.2 Identification of the CD4+ATR+ T-cells in human peripheral blood 
The mononuclear cells obtained either from whole blood of healthy donors or patients 
with HF, were subjected to flow cytometric analysis. The frequency of CD4+ T cells in 
peripheral blood of patients with heart failure (Fig. 4.1) showed a significant increase, 
when compared to healthy donors, reflecting the 
importance of this T cell subset for the link be-
tween innate and adaptive immune responses 
during the progression of cardiac remodeling to 
HF. 
Fig. 4.1CD4 expression in human blood mononuclear cells. Mononuclear cells (MNCs) were isolated 
using Ficoll centrifugation method and analyzed by FACS. The frequency of CD4+ T cells is decreased in 
MNCs of patients with ischemic heart failure compared to healthy donors. n= 7 (HF), n=5 (control); no 
significance observed between both groups. Taken from Skorska A et al., JCMM (2015)  
As immunofluorescence analysis of mononuclear cells showed expression of AT2R 
within the CD4+ T cell population (Fig. 4.2), both identified T-cell subpopulations ex-
pressing or lacking the AT2R were sorted accordingly to the CD4+AT2R+ or  the 
CD4+AT2R- T-cell subpopulations.  
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Fig. 4.2 Identification of the AT2R +- expressing T cells in human peripheral blood.  MACS isolated 
CD4+ T cells were cyto-centrifuged, blocked and double-indirect stained with polyclonal rabbit anti- AT2 
antibody  followed with donkey anti- rabbit Alexa Fluor 488 secondary antibody. AT2R+ cells (green), 
nuclei (blue), CD4+AT2R+ (merged), scale bar= 10µm 
 
Representative re-analysis of such sorted T-cell subpopulations in peripheral blood of 
healthy controls and patients with HF and confirmation of the expression of AT2R on 
mRNA level are shown in Figure 4.3 A and B, respectively. 
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Fig. 4.3 Identification of human blood CD4+AT2R+ T cell population.  A. Representative FACS plots of sorted CD4+AT2R+ (1) and CD4+AT2R- (2) T cells from 
peripheral blood of patients with heart failure (HF) and healthy donors (HD).  Taken from Skorska A et al., JCMM (2015)  
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All FACS dot plots showing the analysis of CD4+AT2R+ vs. CD4+AT2R- within the 
CD4+ fraction of mononuclear blood cells, either of healthy donors or patients with HF 
are presented at the end of this thesis as Appendix 1 and 2, respectively. 
 
4.3(continued): B. Predominant AT2R mRNA level in sorted human blood CD4+AT2R+ (vs. 
CD4+AT2R-) T cells, n=3, ***p<0.001. Taken from Skorska A et al., JCMM (2015) 
Further, to study the adaptive distribution of CD4+AT2R+ T cells during cardiac injury, 
the frequency of these cells in peripheral blood of patients with HF was compared with 
that of healthy controls. The frequency of CD4+AT2R+ T cells in blood CD4+ T cells 
was reduced from 2.6 ± 0.2% in healthy controls to 1.7 ± 0.4% in patients with HF 
(Fig.4.4), revealing a potential accumulation of CD4+AT2R+ T cells infiltrating the 
failing heart.  
Due to the essential role of regulatory T cells (Treg) in controlling the immune response 
under physiological and pathological conditions, the expression of the 
immunoregulatory transcription factor FoxP3 and the Treg surface marker CD25 within 
the CD4+AT2R+ T cell subset was investigated. In human CD4+AT2R+ T cells, the 
frequency of FoxP3-positive cells was increased by 2.1-fold (Fig. 4.5 A, p<0.0001). The 
potential to produce anti-inflammatory IL-10 cytokine by both T-cell populations was 
also evaluated, whereby the predominantly IL-10-secreting subset resided within the 
CD4+AT2R+ T-cells and increased by 12.6-fold (healthy donors) and 41.2-fold (heart 
failure) when compared to CD4+AT2R- T cells (p<0.01, p<0.05 respectively) (Fig. 4.5 
B, C). However, no difference in CD25 expression was detected (Fig. 4.5 A, right plot). 
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Fig.4.4 CD4+AT2R+ T cells were reduced in HF patients. *p<0.05, (heart failure, n=9, healthy donors, 
n=27). Representative FACS plots from healthy controls (upper panel) and HF patients (lower panel). 
Taken from Skorska A et al., JCMM (2015) 
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4.3 Characterization of human blood CD4+AT2R+ T cells 
To address a potential cardioprotective role of AT2R, we determined whether AT2R 
influences the regulation of the inflammatory-related cytokines IL-10 and TNF- in the 
CD4+AT2R+ T cell population.  
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Fig. 4.5 Characterization of human blood CD4+AT2R+ T cells. Flow cytometric analysis was per-
formed on gated CD4+AT2R+ and CD4+AT2R- subpopulations of mononuclear cells (MNCs) from 
healthy donors (A, Foxp3, n=8; CD25, n=11); Predominant IL-10 expression was observed in the 
CD4+AT2R+ (vs. CD4+AT2R-) T cells of healthy controls (B, n=6) and HF patients (C, n=7). Increased 
TNF- expression was observed in the CD4+AT2R+ (vs. CD4+AT2R-) T cells of healthy controls (D, 
n=6) but not HF patients (E, n=7). ns, not significant; **p<0.01, ***p<0.001. Taken from Skorska A et 
al., JCMM (2015) 
Upon AngII stimulation, IL-10 expression in the CD4+AT2R+, but not in CD4+AT2R- 
T cells was significantly increased (2.6-fold in comparison to the control group, Fig. 4.7 
A, B), while TNF-  expression in the CD4+AT2R+ T cells was reduced 2.0-fold (Fig. 
4.7 C, D). Both effects were completely abolished by 
the AT2R blocker PD123319. In particular, a highly 
increased level of TNF- expression was observed 
exclusively in the CD4+AT2R+ T cells (Fig. 4.5 D, E). 
In addition to that this T cell subpopulation secreted 
IFN-γ significantly more than those T cells without 
AT2Rs (Fig 4.6).  
Fig. 4.6 Characterization of human blood CD4+AT2R+ T cells. The frequency of IFN-γ - positive 
cells within the CD4+AT2R+ subset is increased in patients with ischemic heart failure compared to 
CD4+AT2R- T cells. n= 3, * p<0.05. Taken from Skorska A et al., JCMM (2015) 
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Fig. 4.7 IL-10 and TNF-  expression in human blood CD4+AT2R+ T cells. Sorted cells were ana-
lyzed after one day of cultivation. AT2R mediated IL-10 production in the CD4+AT2R+ (A) but not in the 
CD4+AT2R- (B) T cells of healthy controls as observed after AT2R stimulation with angiotensin II 
(AngII) in presence or absence of AT2R blocker PD123319 (PD).  
AT2R shows a tendency to downregulate TNF- production in the CD4+AT2R+ (C) but not in 
CD4+AT2R- (D) T cells of healthy donors, as shown after AT2R stimulation with angiotensin II (AngII) 
in the presence or absence of the AT2R blocker PD123319 (PD). ns, not significant;  **p<0.01.  Taken 
from Skorska A et al., JCMM (2015) 
 
A further detailed analysis of the distribution of CD4+AT2R+ T cells within 
CD4+CD44+CD62L- or CD4+CD44+CD62L+ T cell subsets (Fig. 4.8 A, B) showed 
that a significant decrease of blood CD4+AT2R+ T cells in patients with HF was exclu-
sively assigned to the CD4+CD44+CD62L- T cell subset, a known activated T cell frac-
tion located mainly at inflammatory sites(75). 
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Fig. 4.8 Distribution of the CD4+AT2R+ T cells within CD4+CD44+CD62L- or 
CD4+CD44+CD62L+ T cell subsets    A.  A decreased frequency of CD4+AT2R+ T cells within the 
CD4+CD44+CD62L- cell subset was observed in patients with HF. No significant difference was detect-
ed within the CD4+CD44+CD62L+ T cell subset (B). ns, not significant; *p<0.05, n=5. Taken from 
Skorska A et al., JCMM (2015) 
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5 Results – Part II / Rats 
5.1 Identification of CD4+AT2R+ T cells in a rat MI model 
In rats, myocardial infarction was induced by permanent ligature of the left descending 
artery (LAD). These seven day old MI rats enabled to study the relevance of AT2R in 
response to ischemic injury.  Further, the method of cardiac cell isolation with slightly 
altered MACS technology, which had been established during a previous AT2R-related 
project of our group (71) allowed to clarify a potential functional relevance of AT2R for 
cardiac infiltration within CD4+ T cell subsets.  Here, Fig. 5.1 shows the CD4+AT2R+ - 
T cells infiltrating the myocardium, which were mainly detected in the peri-infarct zone.  
 
Fig. 5.1 Identification of CD4+AT2R+ T cells in a rat MI model. Co-localization of AT2R in a fraction 
of infiltrating CD4 T cells in peri-infarct myocardium. Arrows indicate CD4+ (yellow) AT2R+(red) cells. 
Sections were counterstained with DAPI (nuclei, blue). Scale bar = 10µm. (The present staining was 
performed by Ms Stephanie Zirkel within the bachelor thesis, 2011 and included in Skorska A et al., 
JCMM (2015). 
Besides the infarcted myocardium (representative FACS dot plot analysis, Fig. 5.2 and 
middle of the Fig. 5.4), the CD4+AT2R+ T cells were found in circulating blood and 
spleen (Fig. 5.4). In addition, the verification of AT2R expression on the mRNA level in 
sorted CD4+AT2R+ T cells was performed as shown in Fig. 5.3. 
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Fig. 5.2 Identification of CD4+AT2R+ T cells in a rat MI model. Representative FACS plots of post-
infarction cardiac CD4+AT2R+ and CD4+AT2R- T cells.  Taken from Skorska A et al., JCMM (2015) 
 
 
Fig. 5.3  Verification of the AT2R mRNA level. Accumu-
lated AT2R mRNA levels (normalized to beta-actin) in 
sorted post-infarct cardiac CD4+AT2R+ (vs. CD4+AT2R-) 
T cells, n=3, *p<0.05. Taken from Skorska A et al., JCMM 
(2015) 
 
In blood, infarcted heart and spleen, 3.8 ± 0.4 %, 23.2 ± 2.7% and 22.6 ± 2.6% of CD4+ 
cells expressed AT2R, respectively, (Fig. 5.4). Quantitative analysis reveals a significant 
increase of CD4+AT2R+ T cells in post-infarct heart and spleen, whereas it decreased in 
circulating blood. 
Collectively, the CD4+AT2R+ T cell population seems to be recruited selectively and 
adaptively into the myocardium in response to ischemia. 
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Fig. 5.4  Adaptive redistribution of the CD4+AT2R+ T cell population in response to myocardial 
infarction in rats. Frequency of the CD4+AT2R+ T cells in CD4+ T cells of blood (sham, n= 7; MI, 
n=14), heart (sham, n=5; MI, n=12), and spleen (sham, n=3; MI, n=7) was evaluated by flow cytometric 
analysis. *p<0.05, **p<0.01. Taken from Skorska A et al., JCMM (2015). 
 
5.2 The CD4+AT2R+ T cells as immunoregulatory players – in vitro 
A better understanding of the functionality of the detected CD4+AT2R+ in response to 
ischemic insult will enable a selection of ideal and well defined cells for cardiac therapy 
approaches. Therefore, this T cell subpopulation was analysed for expression of the 
immunoregulatory transcription factor FoxP3 (Fig. 5.5, left)  and secretion of the cyto-
kine IL-10 in the CD4+AT2R+ T cells derived from the peripheral blood of rats with MI 
was evaluated (Fig. 5.5, right plot). As shown, the intracellular production of FoxP3 and 
IL-10 was significantly upregulated 4- and 74-fold, respectively, in CD4+AT2R+ T 
cells, when compared with CD4+AT2R- T cells (p<0.05). These increased IL-10 ex-
pression levels in the CD4+AT2R+ T cells were confirmed by real-time PCR analysis of 
IL-10 mRNA (Fig. 5.6).  
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Fig. 5.5 Characterization of CD4+AT2R+ T cells in rats after myocardial infarction. FoxP3 and IL-
10 were significantly upregulated in blood CD4+AT2R+ T cells. *p<0.05, n=5. Taken from Skorska A et 
al., JCMM (2015) 
 
Fig. 5.6 Confirmation of IL-10 mRNA level in CD4+AT2R+ T cells . *p<0.05, n=5. Taken from 
Skorska A et al., JCMM (2015) 
Hence, these data indicate an immunoregulatory potential of CD4+AT2R+ T cells.   
5.3 Cardioprotective role of CD4+AT2R+ T cells - in vivo  
To determine whether the immunoregulatory potential of CD4+AT2R+ T cells has func-
tional relevance in vivo, we evaluated the effects of intramyocardial transplantation of 
splenic CD4+AT2R+ T cells on cardiac remodeling and performance in rats with MI.  
5.3.1 Transplanted T cells were successfully detected in the heart of recipient 
rats 
Initially, splenic CD4+AT2R+ T cells - sorted and stained with Vybrant DiD dye - were 
transplanted into MI-induced rat hearts. Using flow cytometric analysis after two days, 
we could detect an average 2.8% of Vybrant DiD-positive cells as shown on FACS his-
togram, Fig. 5.7. In addition, four weeks after transplantation, the engraftment of the 
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transplanted cells from male donor rats in peri-infarct myocardium of female recipient 
rats was proven via single-color FISH using a Y-chromosome-specific probe (Fig. 5.8). 
 
 
 
 
 
 
Fig. 5.7 Detection of transplanted CD4+AT2R+ T cells in heart tissue of recipient rats 2 days post 
MI. Hearts were excised, digested and direct flow cytometric acquisition was performed.  A representa-
tive FACS histogram shows Vybrant DiD+ cells which were gated on all acquired cardiac mononuclear 
cells. 
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Fig. 5.8 Detection of male donor cells in the myocardium of female recipient rats by fluorescence in 
situ hybridization.   A. Four weeks after cell transplantation, donor cells were detected via fluorescence 
in situ hybridization (FISH), based on probes specific for the Y chromosome.  
Donor nuclei within the recipient heart are numerically labeled (nuclei 1-3). The probes were labeled with 
IDYE
TM
 556 (white) for Y chromosomes. Slides were mounted with VECTASHIELD
 
medium contain-
ing DAPI for counter-staining of nuclei. Z-stack images were obtained via laser scanning confocal mi-
croscopy (LSM 780, Zeiss). Y-chromosomes present within nucleus 1, 2 and 3 are also shown in xz and yz 
positions, respectively (Arrows in B, C and D). Scale bar, 5 µm. Taken from Skorska A et al., JCMM 
(2015) 
5.3.2 Injection of the CD4+AT2R+ T cells effectively improves cardiac 
performance 
For further in vivo characterization of a cardioprotective role of the CD4+AT2R+ T cell 
subpopulation, PV-loop measurements at baseline and during stress (dobutamine) were 
performed. The complete results (hemodynamic parameters, systolic and end-diastolic 
indices) of this evaluation are shown in the end of this chapter (Tab. 5.1). The data of 
cardiac catheterization of the recipient group in which the CD4+AT2R+ T cells were 
intramyocardially injected showed a significant improvement in cardiac performance 
when compared with CD4+AT2R- T cells and control (saline) groups. In detail, the 
ejection fraction at steady-state of MI plus CD4+AT2R+ animals was increased by 1.5-
fold and 1.2-fold, compared with control and MI plus CD4+AT2R- animals, respective-
ly (Fig. 5.9A and Tab. 5.1). An additional parameter relevant for cardiac systolic func-
tion, namely the maximal peak rate of LVP (dP/dtmax, mmHg/s) under both baseline 
and stress conditions was increased in the CD4+AT2R+. At baseline, respective values 
were enhanced 1.7-fold and 1.4-fold as compared to the control and the CD4+AT2R- 
groups (Fig. 5.9A).  Under stress, the values were elevated 1.2-fold and 1.3-fold in 
comparison to the control and the CD4+AT2R- groups (Fig. 5.9B and Tab. 5.1). 
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Fig. 5.9 Assessment of left ventricular functions in recipient MI rats via pressure-volume loops. 
Intramyocardial transplantation of splenic CD4+AT2R+ T cells led to an increase in ejection fraction (EF) 
at steady state and a maximal peak rate of LVP (dP/dtmax, mmHg/s) under both baseline and stress condi-
tion (Dobutamine, 10µg/min/kg) (A, B), and improved diastolic indices including reduced time during 
relaxation (Tau) at steady state and improved minimal (-dP/dtmin, mmHg/s) peak rate under stress condi-
tion (C, D) as evaluated with conductance-catheter method. Around 2.5x10
5
 splenic cells one of the T cell 
subpopulation were injected in 50µl saline into the border zone. MI+(Saline), n=10, MI+(CD4+AT2R+), 
n=10; MI+(CD4+AT2R-), n=15; ns: not significant, *p<0.05, **p<0.01. Taken from Skorska A et al., 
JCMM (2015) 
Adoptive transfer of CD4+AT2R+ T cells also markedly improved diastolic indices as 
shown by a reduced relaxation time at steady state (Tau, from 17.0 ± 1.3 to 11.0 ± 1.9; 
Fig. 5.9C). It likewise improved the minimal peak rate (-dP/dtmin, mmHg/s) under 
stress conditions from  -6808 ± 292.2 to -5408 ± 296.0 when compared with the 
CD4+AT2R- animal group (Fig. 5.9D and Tab. 5.1).  
5.3.3 Transplanted CD4+AT2R+ T cells ameliorate cardiac remodeling 
The CD4+AT2R+ T cells seemed to be therapeutically effective due to their significant 
influence on cardiac remodeling in recipient rats when compared to controls. In addi-
tion, CD4+AT2R+ T cells from the same donor rats, led to a significant reduction of 
infarction size (1.8- and 1.2- fold, respectively, Fig. 5.10). No significant differences 
were observed between the control and the CD4+ATR- groups (p=0.3171). Representa-
tive images of heart slices stained with Sirius Red/ Fast Green are presented in the lower 
panel of this figure. 
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Fig. 5.10 Effects of CD4+AT2R+ T cells on cardiac injury in recipient MI rats. Intramyocardial 
transplantation of splenic CD4+AT2R+ T cells (vs. MI+(Saline) and CD4+AT2R-) significantly reduced 
infarction size in recipient MI rats four weeks after transplantation. Therapy groups obtained around 
2.5x10
5
 splenic cells, either of CD4+AT2R+ or CD4+AT2R-, resuspended in 50µl saline and injected into 
a border zone. Control group received only 50µl saline. Representative ventricular cross sections of in-
farct areas are shown in lower panels.  *p<0.05, **p<0.01; n=8; scale bar=500µm. Taken from Skorska A 
et al., JCMM (2015) 
Overall, these data support a cardioprotective role for the CD4+AT2R+ T cell popula-
tion by ameliorating post-infarction inflammatory injury in vivo.  
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 MI+(Saline), n=10 MI+(CD4+AT2R+), 
n=10 
MI+(CD4+AT2R-), n=15 P Value 
 Baseline Dobutamine Baseline Dobutamine Baseline Dobutamine P1 P2 P3 P4 P5  P6 
Hemodynamic 
parameters 
      
Body weight [g] 252± 46.9 274.1 ± 5.902 279.8 ± 5.257 ns 
HR [bmp] 384.1 ± 16.09 424.8 ± 14.60 370.1 ± 
15.38 
434.9 ± 7.232 387.2 ± 9.814 436.1 ± 7.292 ns ns ns ns ns ns 
Pmax [mmHg] 93.17 ± 6.47 109.3 ± 3.912 105.6 ± 
5.159 
117.3 ± 3.802 92.08 ± 3.027 108.4 ± 2.341 ns ns <0.05 
* 
ns ns <0.05 * 
PES [mmHg] 88.49 ± 7.133 103.3  ± 4.444 93.14 ± 
6.692 
104.0 ± 4.068 77.79 ± 2.804 91.23 ± 2.915 ns ns <0.05 
* 
ns <0.05 
* 
<0.05 * 
PED [mmHg] 9.686 ± 0.927 9.578 ± 0.774 11.66 ± 
0.9256 
10.80 ± 0.7961 14.25 ± 1.154 12.83 ± 0.9883 ns <0.01 
** 
ns ns <0.05 
* 
   ns 
ESV [µl] 148.7 ± 13.26 121.7 ± 13.49 143.6 ± 
12.48 
59.54 ± 6.920 133.1 ± 8.838 114.7 ± 20.09 ns ns ns <0.01** ns ns 
EDV [µl] 206.4 ± 13.13 201.8 ± 11.27 224.5 ± 
13.88 
244.4 ± 18.18 289.7 ± 28.82 241.5 ± 20.02 ns <0.05 
* 
ns ns ns ns 
SV [µl] 73.90 ± 5.491 106.4 ± 13.37 124.5 ± 
8.259 
185.0 ± 15.86 152.5 ± 16.75 157.8 ± 15.81 <0.01 
** 
<0.01 
** 
ns <0.01 
** 
<0.05 
* 
ns 
CO (µl/min) 30430 ± 3993 48340 ± 6979 54190 ± 
5533 
79890 ± 6541 56940 ± 5903 69290 ± 7054 <0.01 
** 
<0.01 
** 
ns <0.01 
** 
<0.05 
* 
ns 
Systolic indices        
EF (%) 36.80  ± 
3.171 
49.90 ± 5.448 55.75 ± 
3.851 
69.54 ± 4.880 44.74 ± 2.960 57.02 ± 4.081 <0.01** ns <0.05 
* 
<0.05 * ns ns 
dP/dtmax (mmHg/s) 3828 ± 496.6 8946 ± 714.5 6370 ± 700.1 10690 ± 669.7 4620 ± 304.3 8444 ± 439.2 <0.05 * ns <0.05 
* 
ns ns <0.01** 
SW (µl x mmHg) 4597 ± 661.5 8075 ± 1241 8740 ± 653.4 12910 ± 1676 7897 ± 813.0 13430 ± 1333 <0.01** <0.01 
** 
ns <0.05 * <0.05 
* 
ns 
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 MI+(Saline) MI+(CD4+AT2R+) MI+(CD4+AT2R-) P Value 
 Baseline Dobutamine Baseline Dobutamine Baseline Dobutamine P1 P2 P3 P4 P5  P6 
Diastolic  
indices 
      
-dP/dtmin 
(mmHg/s) 
-4736 ± 
747.8 
-5689 ± 447.1 -5333 ± 
570.8 
-6808 ± 292.2 -4298 ± 293.9 -5408 ± 296.0 ns ns ns <0.05* ns <0.01** 
Tau (msec) 14.32 ± 1.250 11.96 ± 0.920 11.03 ± 
1.866 
10.40 ± 1.482 16.99 ± 1.257 12.98 ± 0.9085 ns ns <0.05 
* 
ns ns ns 
Fig.5.11: Hemodynamic characteristics. Hemodynamic characteristics measured in the left ventricular artery using pressure-volume loop (P/V-loop) method in 4-
week-old rats, which undergone LAD ligation plus saline, intra-myocardial transplantation with splenic CD4+AT2R+ or CD4+AT2R- T cells. Mean ± SEM, P1: 
MI+CD4+AT2R+ vs. MI+Saline (Baseline), P2: MI+CD4+AT2R- vs. MI+Saline (Baseline), P3: MI+CD4+AT2R+ vs. MI+CD4+AT2R- (Baseline), P4: 
MI+CD4+AT2R+ vs. MI+Saline (Dobutamine), P5: MI+CD4+AT2R- vs. MI+Saline (Dobutamine), P6: MI+CD4+AT2R+ vs. MI+CD4+AT2R- (Dobutamine), ns: not 
significant, Student T-test. Taken from Skorska A et al., JCMM (2015) 
HR: heart rate, Pmax: maximal pressure, PES: end systolic pressure, PED: end diastolic pressure, ESV: end systolic volume, EDV: end diastolic volume, SV: stroke volume, CO: car-
diac output (=SV x HR) , EF: ejection fraction, dP/dtmax: maximum rate of pressure change in left ventricle (LV), -dP/dtmin (mmHg/s): minimum rate of pressure change in LV,  SW: 
stroke work, Tau: isovolumic relaxation of time 
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6 Discussion  
MI is a frequent cause of heart failure and death. A vast body of evidence showed AngII 
as a major inflammatory agent, acting through modulation of responses of immune and 
inflammatory cells. Actions of AngII are mediated by two receptors, AT1R and AT2R. 
Research on the renin-angiotensin system with respect to cardiac diseases, in particular 
on actions of angiotensin II via the AT2 receptor, is constantly increasing. Therefore, the 
understanding of the crosstalk between the RAS system and the immune system, espe-
cially the participating (immunocompetent) cells was the major topic in the present 
study.  
In this thesis, for the first time AT2R expression on CD4+ T cells of humans as well as 
rats was assessed and its regulation in cardiac disease was described. AT2R expression 
on human peripheral blood CD4+ T cells was higher in healthy donors than in HF pa-
tients. In a rat MI model displaying cardiac remodeling with fibrosis/elevated collagen 
density and loss of heart function, as is typical for HF, CD4+AT2R+ T cell number was 
increased in the heart and spleen but diminished in blood compared to sham-treated 
animals. Our findings are in accordance with previous reports of elevated AT2R levels 
in the adult heart after MI induction (72) and specific AT2R activation after MI induc-
tion (73). Whereas previous work has mostly addressed AT2 receptor levels in whole 
tissues: Altarche-Xifro et al. (2009) showed ATR up-regulation in c-kit+ stem cells of 
rats subjected to MI, and Curato et al. (2010) detected splenic AT2R+ - expressing CD8 
T cells. Based on this and on our novel findings in animal models, it is likely that the 
mobilization of CD4+AT2R+ T cells to the heart after RAS activation may cause their 
reduction in peripheral blood. Given previous observations of AT2R stimulating cell 
differentiation and migration (72,76), it seems likely that AT2R is actively involved in 
the selective extravasation of effector CD4+AT2R+ T cells into injured myocardium. 
The elevated levels of AT2R detected on CD4+ T cells in the infarcted heart might be 
the consequence of that. Moreover, flow cytometric analysis of the frequency of CD4+ 
T cells in peripheral blood of patients with heart failure showed a significant increase 
compared to healthy donors, indicating the importance of this T cell subset during the 
progression of cardiac remodeling to HF. It has long been appreciated that T cell subsets 
in inflammatory sites, like cardiac allografts and ischemic injury (77,78) down-regulate 
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CD62L (also known as L-selectin), the lymphoid homing receptor, but up-regulate 
CD44, a marker of activated effector T cells (79). A reduction of CD4+AT2R+ T cells 
was also found in blood CD44+CD62L- effector T cells of patients with HF, but not in 
CD44+CD62L+ cells, confirming our hypothesis that AT2R is influenced specifically 
on T cell subsets involved in cardiac inflammation and regeneration. 
Pathologic processes such as congestive heart failure lead to remodeling of the heart and 
reduce the ability to function as a syncytium (80).  Moreover, contractility is also influ-
enced by expansion of the extracellular matrix with fluid, as observed in inflammatory 
states. These so-called intracellular edema results in functional ischemia and irreversible 
damage of the myocardium leading to scar formation. This damage is due to the abnor-
mal failure of self-tolerance, where infiltrated lymphocytes are reacting against self-
antigens. To elucidate the role that infiltrating CD4+AT2R+ T cells may play in this 
process, we analyzed inflammatory properties of these cells. CD4+AT2R+ T cells from 
MI rats as well as healthy and HF human donors overexpressed FoxP3 compared to 
CD4+AT2R- T cells, whereas CD25 remained unchanged. Treg cells were reported to 
contribute to prevention of autoimmune disease through expression of FoxP3 (81), and 
Tang et al.(82)(83) observed reduced CD4+CD25+ FoxP3+CD127low Treg cells in 
heart failure, suggesting that defective Treg might be involved in disturbed immune 
homeostasis and also responsible for uncontrolled T cell activation in HF. While AT2R 
does not seem to be selective for Treg, the detected overexpression of FoxP3 suggests 
an anti-inflammatory potential of CD4+AT2R+ cells. Thus, it underlines the importance 
of FoxP3 in the actions mediated via AT2R. Very recently, publications reported factors 
involved in FoxP3 expression, such as Sp1, NFATc2, AP1 and STAT5 binding to the 
Foxp3 promotor (83) (75). Also our RT-PCR data showed an elevated trend towards 
NFATc2 mRNA in CD4+AT2R+ T cells compared to CD4+AT2R- T cells although not 
at a statistically significant level (data not shown).   
One of the immunosuppressive properties characteristic for Treg cells is the potential to 
secrete IL-10 (84). Noteworthy, CD4+AT2R+ T cells produced significantly more IL-10 
than CD4+AT2R- T cells in vitro, and AngII stimulation further induced IL-10 up- as 
well as TNFα and IFN-γ downregulation in these cells. AT2R was required for this regu-
lation, as evident from selective inhibition with the AT2R antagonist, PD123319. The 
anti-inflammatory cytokine IL-10 activates JAK and/or STAT proteins leading to an 
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induction of JAK1/Tyk2 proteins, which further activate STAT3 and SOCS3 responsible 
for central anti-inflammatory responses of IL-10 in macrophages. IL-10 indirectly in-
hibits NF-kB activation induced via TNF-α (Fig. 6.1) (85). The elevated IL-10 secretion 
by CD4+AT2R+ T cells might inhibit the activation of TNF-α and/or IFN-y.  
Here we postulated that when the actions of IFN-γ signaling are blocked, due to the ele-
vated level of IL-10 cytokines, it plays an important role in inhibitory Smad7 down-
stream pathways, interfering with Smad2 and Smad3 binding and elicits a reduced in-
flammatory response (Fig.6.1). CD4+AT2R+ T cells markedly exerted cytokine 
secretion when compared to CD4+AT2R- T cells, which is likely mediated by AT2R. 
This indicates CD4+AT2R+ T cells as being regulatory cells.  
 
Fig. 6.1 Potential interactions of the pro- and anti-inflammatory cytokines towards immune re-
sponse under ischemia conditions. The CD4+AT2R+ T cells reveal immunoregulatory properties, due to 
their elevated secretion of IL-10 and downregulation in production of pro-inflammatory cytokines (TNF-
α, IFN-γ). Additionally, the predominant levels of IL-10 might inhibit IFN-γ actions promoting the anti-
inflammatory actions. SOCS3 – suppressor of cytokine 3; JAK – Janus kinase; STAT - signal transducers 
and activators of transcription; TRAF – TNF receptor-associated factor; AP1 – activator protein 1; NF-
кB – nuclear factor “kappa-light-chain-enhancer” of activated B cells; Tyk -  tyrosine kinase; Smad -  
intracellular protein of TGF β family; TGF-β – transforming growth factor- β; IL – interleukin; IFN-γ – 
interferon-γ; TNF-α -  tumor necrosis factor- alpha. 
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Taking into account the above described evidence of CD4+AT2R+ T cell anti-
inflammatory potential, especially in HF individuals or under RAS stimulation, we hy-
pothesized that CD4+AT2R+ T cells of MI rats transplanted to recipient MI hearts 
might improve cardiac function. Indeed, pressure and volume assessment in the left 
ventricles of rats with MI plus injected splenic CD4+AT2R+ T cells showed improved 
myocardial performance in comparison to those rats with CD4+AT2R- injected cells. 
Hearts derived from rats with MI+(CD4+AT2R+) presented a significant reduction in 
infarct size compared to hearts from the MI+(CD4+AT2R-) group. Our findings align 
well with studies of AT2R stimulation with Compound 21 (C21), which led to an im-
provement in hemodynamics and reduction of infarct size due to C21-suppressed in-
flammatory actions as shown by significant decrease of cytokines (IL-1β, MCP-1, IL-2, 
IL-6) in plasma and peri-infarct zone(73). 
In an animal model of autoimmune diabetes, injected regulatory T cells were markedly 
present in lymph nodes rather than at the site of inflammation (86). In contrast, in a 
model of multiple sclerosis, transplanted cells accumulated directly at the site of in-
flammation in the nervous system (87). Therefore, it remains to be clarified whether the 
beneficial actions of transferred CD4+AT2R+ cells observed by us occur directly in the 
inflamed heart or whether draining lymph nodes are involved. 
Irrespective of the final site of action, we provide evidence that AT2R+CD4+ cells pos-
sess high regenerative potential. Their selective stimulation may open up promising 
treatment opportunities for cardiac therapy. Here, the AT2R agonist Compound 21 may 
be a suitable candidate for future applications (88).  
In sum, we identified CD4+AT2R+ as a novel regulatory T cell subset with beneficial 
impact on cardiac function after MI. CD4+AT2R+ T cells were upregulated in HF pa-
tients as well as MI rats and displayed anti-inflammatory properties (induction of FoxP3 
and IL-10, downregulation of TNF-α and IFN-γ) compared to CD4+AT2R- cells. Myo-
cardial transplantation of CD4+AT2R+ T cells led to improved cardiac function and 
reduced infarct size in a rat MI model. Our results introduce the AT2 receptor as a bene-
ficial AngII-mediating receptor, implying that CD4+AT2R+ cells are a highly promising 
population for regenerative therapy, as they are suitable for myocardial transplantation, 
pharmacological AT2R activation or a combination thereof. 
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7 Conclusion 
Taken together, our study contributes to the understanding of CD4+AT2R+ cell function 
after MI. We identified this potential novel regulatory T cell subset, which expresses 
FoxP3 and various cytokines (i.e. IL-10, TNF-α, IFN-γ), improves cardiac function and 
reduces infarct size. The underlying results indicate the AT2 receptor as a beneficial 
AngII-mediating receptor of the RAS system, implying that CD4+AT2R+ cells can be 
included in therapeutic approaches for the treatment of cardiac diseases, due to its 
upregulation in the infarcted state. The application of this T cell subset may improve the 
healing process of compromised heart tissue and contribute to a better quality of life in 
affected patients.  
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Appendix 1 and Appendix 2. FACS dot plots of healthy donors and patients with heart failure. Mononuclear cells (MNCs) were isolated from human peripheral 
blood using Ficoll centrifugation and stained with mouse anti-human CD4-PE and goat polyclonal anti-AT2R followed by indirect staining with secondary antibody 
anti-goat Alexa Fluor 488. Cells were analyzed and sorted using a BD FACS Aria II. Healthy donors, n=28; Heart failure n=9. Taken from Skorska A et al., JCMM 
(2015) 
 
 
